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Abstract
The emergence and proliferation of Gram-negative bacteria expressing -lactamases is a
significant threat to human health. -Lactamases are enzymes that degrade the -lactam
antibiotics (e.g., penicillins, cephalosporins, monobactams, and carbapenems) that we use to treat
a diverse range of bacterial infections. Specifically, -lactamases catalyze a hydrolysis reaction
where the -lactam ring common to all -lactam antibiotics and responsible for their
antibacterial activity, is opened, leaving an inactive drug. There are two groups of -lactamases:
serine enzymes that use an active site serine residue for -lactam hydrolysis and metalloenzymes
that use either one or two zinc ions for catalysis. Serine enzymes are divided into three classes
(A, C, and D), while there is only one class of metalloenzymes, class B. Clavulanic acid,
sulbactam, and tazobactam are -lactam-based BLIs that demonstrate activity against class A
and C -lactamases; however, they have no activity against the class A KPC and MBLs, NDM
and VIM. Avibactam and vaborbactam are novel BLIs approved in the last two years that have
activity against serine carbapenemases (e.g., KPC), but do not inhibit MBLs. The overall goals
of this project were to use X-ray crystallography to study the catalytic mechanism of serine lactamases with -lactam antibiotics and to understand the mechanisms behind the broadspectrum inhibition of class A -lactamases by avibactam and vaborbactam. This project also set
out to find novel inhibitors using molecular docking and FBDD that would simultaneously
inactivate serine -lactamases and MBLs commonly expressed in Gram-negative pathogenic
bacteria.
ix

The first project involved examining the structural basis for the class A KPC-2 lactamase broad-spectrum of activity that includes cephalosporins and carbapenems. Three
crystal structures were solved of KPC-2: (1) an apo-structure at 1.15 Å; (2) a complex structure
with the hydrolyzed cephalosporin, cefotaxime at 1.45 Å; and (3) a complex structure with the
hydrolyzed penem, faropenem at 1.40 Å. These complex structures show how alternative
conformations of Ser70 and Lys73 play a role in the product release step. The large and shallow
active site of KPC-2 can accommodate a wide variety of -lactams, including the bulky
oxyimino side chain of cefotaxime and also permits the rotation of faropenem’s 6-1Rhydroxyethyl group to promote carbapenem hydrolysis. Lastly, the complex structures highlight
that the catalytic versatility of KPC-2 may expose a potential opportunity for drug discovery.
The second project focused on understanding the stability of the BLI, avibactam, against
hydrolysis by serine -lactamases. A 0.83 Å crystal structure of CTX-M-14 bound by avibactam
revealed that binding of the inhibitor impedes a critical proton transfer between Glu166 and
Lys73. This results in a neutral Glu166 and neutral Lys73. A neutral Glu166 is unable to serve as
a general base to activate the catalytic water for the hydrolysis reaction. Overall, this structure
suggests that avibactam can influence the protonation state of catalytic residues.
The third project centered on vaborbactam, a cyclic boronic acid inhibitor of class A and
C -lactamases, including the serine class A carbapenemase KPC-2. To characterize
vaborbactam inhibition, binding kinetic experiments, MIC assays, and mutagenesis studies were
performed. A crystal structure of the inhibitor bound to KPC-2 was solved to 1.25 Å. These data
revealed that vaborbactam achieves nanomolar potency against KPC-2 due to its covalent and
extensive non-covalent interactions with conserved active site residues. Also, a slow off-rate and

x

long drug-target residence time of vaborbactam with KPC-2 strongly correlates with in vitro and
in vivo activity.
The final project focused on discovering dual action inhibitors targeting serine
carbapenemases and MBLs. Performing molecular docking against KPC-2 led to the
identification of a compound with a phosphonate-based scaffold. Testing this compound using a
nitrocefin assay confirmed that it had micromolar potency against KPC-2. SAR studies were
performed on this scaffold, which led to a nanomolar inhibitor against KPC-2. Crystal structures
of the inhibitors complexed with KPC-2 revealed interactions with active site residues such as
Trp105, Ser130, Thr235, and Thr237, which are all important in ligand binding and catalysis.
Interestingly, the phosphonate inhibitors that displayed activity against KPC-2, also displayed
activity against the MBLs NDM-1 and VIM-2. Crystal structures of the inhibitors complexed
with NDM-1 and VIM-2 showed that the phosphonate group displaces a catalytic hydroxide ion
located between the two zinc ions in the active site. Additionally, the compounds form extensive
hydrophobic interactions that contribute to their activity against NDM-1 and VIM-2. MIC assays
were performed on select inhibitors against clinical isolates of Gram-negative bacteria
expressing KPC-2, NDM-1, and VIM-2. One phosphonate inhibitor was able to reduce the MIC
of the carbapenem, imipenem 64-fold against a K. pneumoniae strain producing KPC-2. The
same phosphonate inhibitor also reduced the MIC of imipenem 4-fold against an E. coli strain
producing NDM-1. Unfortunately, no cell-based activity was observed for any of the
phosphonate inhibitors when tested against a P. aeruginosa strain producing VIM-2. Ultimately,
this project demonstrated the feasibility of developing cross-class BLIs using molecular docking,
FBDD, and SAR studies.

xi

Chapter 1:
Introduction

1.1 Bacterial Antibiotic Resistance
Bacteria are single-celled organisms that are ubiquitous throughout the earth, living in
diverse environments ranging from hot springs and glaciers to the human body. The majority of
bacteria are non-pathogenic; however, there are certain bacteria that have the ability to cause
disease in humans [1, 2]. These pathogenic bacteria cause a variety of illnesses such as meningitis,
pneumonia, gastroenteritis, and sepsis. Usually these illnesses are life-threatening, but the
discovery of drugs known as antibiotics has dramatically decreased the rates of death. Antibiotics
are drugs that selectively target bacteria and either inhibit or kill them by stopping a vital cellular
process (Fig. 1.1) [3]. The modern antibiotic era began almost ninety years ago with the discovery
of penicillin by Alexander Fleming. In 1928, Fleming serendipitously observed mold growing in
dishes of Staphylococcus bacteria. Around this mold, no bacterial growth occurred. This led
Fleming to hypothesize that the mold was secreting some substance that inhibited bacterial growth.
Ultimately, the mold was identified as Penicillium rubens, and the name “penicillin” was used to
describe the antibacterial substance [4, 5]. Several years later, large-scale production of penicillin
was carried out, which provided the medical community a treatment option for a wide variety of
bacterial infections [5]. Subsequently, many other classes of antibiotics such as aminoglycosides,
sulfonamides, tetracyclines, macrolides, and quinolones were discovered and developed that added
to our antibiotic arsenal [6, 7].
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Despite the successes surrounding the introduction of penicillin, there were some concerns
about its use. In 1940, researchers reported that an Escherichia coli strain could inactivate
penicillin by producing an enzyme known as penicillinase [8]. This observation was also
documented in 1942 when hospitalized patients infected with strains of Staphylococcus aureus did
not respond to penicillin treatment [9, 10]. Over the last fifty years, resistance to penicillin has
skyrocketed, with an estimated 90-95% of S. aureus clinical isolates throughout the world
demonstrating resistance to penicillin [11]. This resistance trend was also mirrored against other
antibiotics. For example, aminoglycosides were discovered in 1946 and in the same year,
resistance was already observed; tetracyclines were discovered in 1944, and by 1950, resistance
was seen in the clinic [12].
According to the Centers for Disease Control and Prevention (CDC), almost all bacterial
infections are becoming increasingly resistant to the antibiotic therapy of choice [13]. In 2013, the
CDC stated that the human race has entered the “post-antibiotic era”, in which infections typically
cured by antibiotics are now becoming lethal [14]. The CDC estimates that each year in the United
States, at least 2 million people contract a bacterial infection that is resistant to one or more
antibiotics designed to treat that infection. Approximately 23,000 individuals die each year as a
direct result of those antibiotic-resistant infections, though this number may be an underestimate
because deaths attributed to HIV, cancer, or surgery, may in fact be due to an antibiotic-resistant
bacterial infection [13]. Antibiotic resistance poses not only a health threat, but also an economic
impact. In many cases, individuals diagnosed with an antibiotic-resistant infection will often
require longer hospital stays, prolonged treatment, and more doctor visits than individuals with an
infection that responds to antibiotic treatment. As a result, studies have estimated the economic
impact of antibiotic resistance to be in the range of $6-60 billion annually [15, 16]. Therefore,
2

antibiotic resistance is quickly becoming an emerging global health epidemic and economic
burden.

1.2 Resistance to -Lactam Antibiotics
Bacteria can utilize numerous mechanisms to become resistant to antibiotic treatment. The
four main mechanisms of antibiotic resistance include: (1) enzymatic inactivation or modification
of the drug, (2) target modification, (3) decreased drug penetration, and (4) bypass of pathways
(Fig. 1.2) [17]. The first antibiotic resistance mechanism described was enzymatic inactivation of
penicillin by penicillinases [18]. Penicillin belongs to a class of antibiotics known as -lactams,
which also includes cephalosporins, monobactams, and carbapenems (Fig. 1.3) [19]. All -lactam
antibiotics possess a four-membered -lactam ring at the core of their structure that is crucial to
their antibacterial activity [20, 21]. -Lactam antibiotics are broad-spectrum antibiotics and work
by interfering with the synthesis of the bacterial cell wall. The cell wall is vital to the survival of a
bacterium for several reasons. Overall, the major functions of the bacterial cell wall are to help
maintain the cell shape and protect the cell from osmotic changes that it may encounter in the
environment [22-24]. The bacterial cell wall is composed of peptidoglycan, an organic polymer
consisting of an interlocking network of the polysaccharides N-acetylglucosamine (NAG) and Nacetylmuramic acid (NAM), cross-linked by short peptides [24]. The extensive cross-linking of
peptidoglycan greatly contributes to the strength of the bacterial cell wall. This cross-linking
process is catalyzed by a group of enzymes known as penicillin-binding protein (PBPs). PBPs are
also known as DD-transpeptidases since they are responsible for forming the peptide cross bridge
between chains of NAG and NAM [25, 26].
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Some bacteria can be classified according to the chemical and physical properties of their
cell wall. This method is based on the Gram stain developed by Danish physician Hans Christian
Gram in 1884. The Gram stain differentiates between Gram-positive and Gram-negative bacteria
by staining these cells violet or pink. Gram-positive bacteria have a thick layer of peptidoglycan
in their cell wall, and thus can retain the crystal violet dye when stained; whereas Gram-negative
bacteria have a thinner peptidoglycan layer, which cannot retain the crystal violet dye when
decolorized, and are subsequently counterstained pink [27]. The Gram stain is a very useful
technique in identifying bacteria; however, not all bacteria can be Gram stained. For example,
Mycobacterium species cannot be Gram stained due to the presence of mycolic acids in their cell
walls, which prevent uptake of the dyes used [28].
The bacterial cell wall presents a promising target to antibiotics for a variety of reasons.
Firstly, human cells lack cell walls, meaning that cell wall synthesis inhibitors will selectively
target only bacterial cells [29]. Secondly, the cell wall is essential to the survival of a bacterium,
and inhibiting its synthesis will ultimately result in cell death [22-24]. -Lactam antibiotics
interfere with the cross-linking reaction that gives the cell wall its rigidity. -Lactam antibiotics
resemble the natural substrate of PBPs, the D-Ala-D-Ala group found at the end of the pentapeptide
precursors of peptidoglycan. This structurally similarity enables -lactam antibiotics to bind to
PBPs and irreversibly acylate an active site serine residue [25].
Although -lactam antibiotics have been a mainstay of treatment for a diverse range of
bacterial infections, they are becoming less effective due to the emergence of antibiotic resistance.
In general, there are three strategies that bacteria use to become resistant to -lactam antibiotics:
(1) the synthesis of -lactam degrading enzymes known as -lactamases, (2) alteration of PBP
targets, and (3) the active transport of -lactam molecules out of the cell via membrane-associated
4

proteins known as efflux pumps (Fig. 1.4) [25]. The most common mechanism of -lactam
resistance among Gram-negative bacteria is the production of -lactamases that degrade the
antibiotic before it can reach its PBP target [19, 30]. -Lactamases provide antibiotic resistance to
bacteria by catalyzing the hydrolysis of the four-membered -lactam ring that is shared by all lactam antibiotics. Once the -lactam ring is hydrolyzed, the antibiotic is no longer effective [19].
What makes -lactamases even more worrisome is the fact that the genes encoding them are
commonly located on mobile genetic elements, such as plasmids and transposons, which facilitates
their spread among bacteria, further contributing to the problem of antibiotic resistance [31].

1.3 -Lactamase Classification
-Lactamases can be classified using two different schemes. The first scheme classifies lactamases according to their substrate profiles and inhibition properties. This groups -lactamases
into

penicillinases,

cephalosporinases,

extended-spectrum

-lactamases

(ESBLs),

and

carbapenemases. Also taken into consideration is whether the -lactamases are inhibited by the lactamase inhibitors (BLIs) clavulanic acid, sulbactam, and tazobactam. Additionally, inhibition
by the chelating agent ethylenediaminetetraacetic acid (EDTA) indicates the -lactamases are
metalloenzymes [32]. The second and more commonly used classification scheme for lactamases is known as the Ambler classification, which groups -lactamases into four classes (A,
B, C, and D) based upon their primary structure (Fig. 1.5) [32, 33]. Classes A, C, and D include
enzymes that use an active site serine residue to carry out hydrolysis of -lactam substrates,
whereas class B -lactamases (divided into subclasses B1, B2, and B3) are metalloenzymes that
use one or two zinc ions to perform -lactam hydrolysis [32-34].
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The most abundant -lactamases belong to class A, comprising more than 550 enzymes.
Among these enzymes, the most frequently encountered -lactamases include TEM, SHV, CTXM, and KPC [32, 35, 36]. Like PBPs, class A -lactamases form an acyl–enzyme complex with lactam antibiotics; however, unlike PBPs, class A -lactamases can carry out a deacylation
reaction, liberating the enzyme and resulting in the release of a hydrolyzed -lactam product (Fig.
1.6) [36-38]. There are key residues that are implicated in the acylation and deacylation reaction
of class A -lactamase catalysis. It has been proposed that Glu166 serves as the general base in
the acylation part of catalysis by deprotonating the catalytic Ser70 via a water molecule before
Ser70 attacks the -lactam ring [39]. Glu166 is also involved in the deacylation reaction, where it
serves as a base to activate a hydrolytic water molecule [40]. Mutagenesis of Glu166 impairs
deacylation; however, Glu166 mutant enzymes are still able to form acyl–enzyme complexes [39].
This suggests that another active site residue, Lys73, which is located near other catalytic residues
(Ser70, Ser130, and Glu166), can act as the general base during the acylation step. Ultrahigh
resolution and neutron crystal structures of the Toho-1 E166A acyl–intermediate confirmed that
Lys73 was neutral and can serve as the general base for the acylation reaction [41].
Class C -lactamases are another major cause of -lactam resistance among bacterial
pathogens. Members of the class C family include the clinically relevant -lactamases ADC,
AmpC, CMY, and FOX [32, 42]. Overall, class C -lactamases behave very similarly to class A
-lactamases in terms of catalysis. Class C -lactamases use an active site serine residue (Ser64)
to attack the -lactam ring. Studies have suggested that two other residues play an important role
in the activation of Ser64 for nucleophilic attack: Lys67 and Tyr150. Other studies have also
proposed that the substrate may play a role in activation of Ser64 [43, 44]. For the deacylation
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reaction, computational studies have suggested a Tyr150/Lys67 general base mechanism. Tyr150
is largely protonated during the acyl–enzyme complex, in which prior to -lactam hydrolysis,
transfers a proton to Lys67. This proton transfer allows Tyr150 to align towards and activate the
catalytic water, while maintaining a hydrogen bond (HB) with Lys67. The catalytic water then
carries out a nucleophilic attack on the carbonyl carbon of the acyl–enzyme complex, resulting in
-lactam hydrolysis [45].
Class D -lactamases, like classes A and C, are serine enzymes, but interestingly, the
catalytic mechanism of class D -lactamases differs markedly [46, 47]. Class D -lactamases are
commonly referred to as OXA enzymes, due to their ability to hydrolyze oxacillin, a penicillin
derivative. Class D -lactamases include over 400 members, with clinically important enzymes
such as OXA-24/40, OXA-48, and OXA-58 found in a variety of Gram-positive and Gramnegative pathogens [48-51]. Class D -lactamases use an active site Ser70 to carry out nucleophilic
attack on the -lactam ring; however, an unusual modification of Lys73 is observed in various
crystal structures. Lys73 undergoes carbamylation, which has been demonstrated to be essential
for both the enzyme acylation and deacylation steps of catalysis [46, 47, 51, 52]. This posttranslational modification of Lys73 is unique to class D -lactamases and has not been observed
in any other class of -lactamase [52]. Another unique property of class D -lactamases is their
susceptibility to inhibition by sodium chloride. Research has suggested that the presence of a Tyr
residue at position 144 is correlated with inhibition by sodium chloride, as mutating Tyr144 to Phe
alleviates sodium chloride inhibition [53, 54].
Although class B -lactamases catalyze the same reaction as class A, C, and D lactamases, the mechanism by which they accomplish this does not involve an active site serine
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residue or formation of a covalent intermediate [55]. Additionally, class B -lactamases have no
sequence or structural similarity to class A, C, and D -lactamases [56]. Rather than using an active
site serine residue, class B -lactamases are metalloenzymes that use zinc for activity. Class B lactamases or metallo--lactamases (MBLs), have as little as 25% sequence identity between some
members; however, multiple crystal structures show that all MBLs have a common fold, known
as an / sandwich fold, with the active site located between domains [57]. The active site of
MBLs supports six residues that can coordinate either one or two zinc ions used in catalysis (Fig.
1.7). MBLs are divided into three subclasses (B1, B2, and B3), which differ from one another
based on amino acid sequence. B1 and B3 enzymes are maximally active when two zincs are
bound in the active site. In B1 and B3 enzymes, the first zinc ion (called Zn1) is coordinated by
three His residues. However, the residues coordinating the second zinc ion (called Zn2) differ
between B1 and B3 enzymes. In B1 enzymes, Zn2 is coordinated by Asp, Cys, and His, whereas
in B3 enzymes, Zn2 is coordinated by Asp, His, and His [57]. B2 enzymes, unlike B1 and B3
enzymes, are most active with only one zinc in the active site, and binding of a second zinc ion is
inhibitory. For B2 enzymes, the inhibitory Zn1 binding site is formed by Asn, His, and His, while
the activating Zn2 binding site is formed by Asp, Cys, and His [58]. B1 and B3 enzymes have a
broad-substrate profile that includes all -lactam antibiotics except aztreonam, while B2 enzymes
selectively hydrolyze carbapenems [59].
B1 enzymes are the most clinically relevant and researched MBLs, and include members
such as NDM-1, IMP-1, and VIM-2 [55]. Catalysis of B1 enzymes begins with binding of the lactam substrate to the zinc metal center, with the carbonyl oxygen of the four-membered -lactam
ring interacting with Zn1, and the carboxyl group on the five- or six-membered fused ring
interacting with Zn2 (Fig. 1.8). A nucleophilic hydroxide ion stabilized and located between Zn1
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and Zn2 is positioned for its attack on the carbonyl carbon of the -lactam ring. Attack of the lactam ring leads to the formation of a tetrahedral intermediate [57]. Ultimately, this tetrahedral
intermediate is broken down; however, the mechanism by which this occurs is still debated. One
proposed mechanism involves direct coordination of the substrate departing amine nitrogen to the
zinc ion. Another hypothesis is that a metal-bound water molecule donates a proton to the amine
nitrogen leaving group, leading to cleavage of the C-N bond [56].

1.4 Carbapenemases
Among all the -lactam antibiotics, carbapenems have the broadest spectrum of activity
against Gram-positive and Gram-negative bacterial pathogens, and are often considered the last
line of therapy against multi-drug resistant infections [60]. Carbapenems (e.g., imipenem,
meropenem, doripenem, and ertapenem) are inherently stable against many different serine lactamases due to a unique chemical property (Fig. 1.9). -Lactams such as penicillins and
cephalosporins have an acylamino substituent attached to the -lactam ring; however,
carbapenems depart from this trend by having a hydroxyethyl side chain, which is key to their
potency [60]. The hydroxyethyl group of carbapenems is attached in the trans-configuration, which
differs from the cis-configuration found in the side chains of penicillins and cephalosporins (Fig.
1.9) [61]. Studies have shown that the trans-hydroxyethyl group prevents the attack of the catalytic
water on the acyl linkage due to electrostatic and steric hindrance, thereby trapping the -lactamase
at the acyl–intermediate stage [60].
Unfortunately, some -lactamases have evolved to include carbapenems in their substrate
profile. These -lactamases commonly belong to classes A (e.g., KPC, GES, NMC-A, IMI, and
SME), B (NDM, VIM, IMP, and SPM), and D (OXA-23, -24/40, -48, -51, -58, and -143)
9

[55,62,63]. Class C -lactamases are not typically classified as carbapenemases due to their weak
hydrolytic activity against carbapenems; however, there are a few cases where carbapenemase
activity has been observed in class C enzymes, most notably with CMY-10 [60, 64].
Of all the class A carbapenemases, the Klebsiella pneumoniae carbapenemase (KPC) is the
most frequently encountered in clinic and causes the most health concern due to its location on
mobile genetic elements such as plasmids and transposons. Although KPC is commonly found in
K. pneumoniae, it is also found in other Gram-negative pathogens, especially those of the
Enterobacteriaceae family [62, 65]. In fact, carbapenem-resistant Enterobacteriaceae (CRE) have
been classified by the CDC as “an important emerging threat to public health” [66]. There are 23
variants of KPC (KPC-2 to KPC-24), with KPC-2 being the most prevalent variant [67, 68].
Compared with noncarbapenemases (e.g., CTX-M, SHV, TEM), the active site of KPC-2 is larger
and shallower, allowing for the accommodation of a wide variety of -lactams, even those with
“bulky” side chains. This property enables KPC-2 to hydrolyze penicillins, cephalosporins,
monobactams, carbapenems, and even the -lactam derived BLIs [69].
Carbapenem-hydrolyzing class D -lactamases (CHDLs) are a clinical problem due to their
ability to compromise the use of carbapenem antibiotics. Most CHDLs are found in isolates of
Acinetobacter baumannii; however, some CHDLs are found in K. pneumoniae and, to a lesser
extent, other members of the Enterobacteriaceae family [63]. OXA-48 is one of the main CHDLs
isolated around the world, and is commonly found in Mediterranean countries, Western Europe,
and Africa [70]. OXA-48 has the highest catalytic efficiency for imipenem out of all the known
class D -lactamases. This observation is reflected in OXA-48-producing K. pneumoniae strains
exhibiting multi-drug resistance patterns, especially towards carbapenems [71]. Further
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complicating matters, OXA-48 is poorly inhibited by clavulanic acid, sulbactam, and tazobactam
[70].
All MBLs can hydrolyze carbapenems and are not inhibited by the classical serine BLIs.
The B1 enzymes NDM and VIM are commonly produced by CRE and Pseudomonas aeruginosa,
two of the biggest threats to clinical therapies [55]. To date, 16 variants of NDM have been
identified, with the major worldwide variant being NDM-1, and 46 variants of VIM have been
discovered, with the most frequent variant being VIM-2 [55, 67, 72]. Interestingly, all MBLs are
unable to hydrolyze the monobactam, aztreonam, which would be an effective therapy against
bacteria solely producing MBLs; however, MBL-producing bacteria commonly produce serine lactamases as well, which can hydrolyze aztreonam. Therefore, aztreonam alone is usually not a
reliable treatment option for MBL-producing bacteria [59, 73].

1.5 Clinically Approved BLIs
A tremendous amount of research has been carried out to discover BLIs that would
hopefully restore the efficacy of the -lactam antibiotics. The first breakthrough occurred during
the mid-1970s via a natural product screen that identified a compound produced by Streptomyces
clavuligerus [74]. This compound was named clavulanic acid and possessed a structure similar to
penicillin, including the -lactam ring. Clavulanic acid is a potent inhibitor of many clinically
important class A -lactamases, and acts synergistically with -lactams to kill -lactamase
producing bacteria. Further research led to the identification of two more BLIs, sulbactam and
tazobactam, that increased the spectrum of activity to include class C -lactamases (Fig. 1.10) [75].
However, there are a few drawbacks to clavulanic acid, sulbactam, and tazobactam, which include:
(1) these inhibitors on their own possess no antibacterial activity [76], (2) the presence of a 11

lactam ring makes these inhibitors susceptible to -lactamase mediated-resistance, and (3) they
have no activity against the serine carbapenemases (e.g., KPC-2 and OXA-48) and MBLs (e.g.,
NDM-1 and VIM-2) [77].
To help address the shortcomings of clavulanic acid, sulbactam, and tazobactam, novel
BLIs are necessary. The first of these novel inhibitors was avibactam, a synthetic
diazabicyclooctane (DBO), non--lactam inhibitor (Fig. 1.10). Unlike the previous inhibitors,
avibactam can inhibit class A (including KPC-2), class C, and some class D -lactamases through
a covalent, reversible mechanism [75, 78]. In 2015, the Food and Drug Administration (FDA)
approved the combination of the third-generation cephalosporin, ceftazidime, with avibactam
(marketed as Avycaz), to treat certain multi-drug resistant bacterial infections [77-79].
Unfortunately, avibactam has no activity against MBLs and some mutations in KPC appear to
confer resistance to ceftazidime/avibactam [80, 81]. Another novel BLI called vaborbactam
(formerly RPX7009), is a cyclic boronic acid compound with potent activity against KPC-2 and
other class A and C enzymes (Fig. 1.10) [75, 77, 82]. Boronic acid compounds have long been
established as potent inhibitors of serine -lactamases due to their ability to form covalent adducts
with the active site serine residue [83]. Similarly, vaborbactam forms a reversible, covalent bond
with the active site serine residue [77]. In 2017, the FDA approved the combination of meropenem
(a carbapenem) with vaborbactam, marketed as Vabomere, for adults with complicated urinary
tract infections, including pyelonephritis caused by CRE [84]. However, like avibactam,
vaborbactam has no activity against MBLs [77]. Therefore, additional research is required to find
an inhibitor with dual serine -lactamase and MBL activity.
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1.6 Fragment-Based Drug Discovery
Discovering novel inhibitors against protein targets is a challenging and time-consuming
endeavor. The drug discovery process can be generally summarized into four stages: (1) target
identification and validation, (2) lead discovery, (3) lead optimization, and (4) clinical trials [85].
Stumbles can be had at any of these stages; however, the hardest part is usually the second stage
of lead discovery [86]. The starting point for lead candidates includes natural products, highthroughput screening (HTS) of large compound libraries, and fragment-based drug discovery
(FBDD) [87]. HTS and FBDD are the most common methods used for lead identification, both
having certain advantages and limitations. The HTS method began in the late 1980s due to a shift
from phenotypic to target-based drug discovery [88]. In HTS, a large number of compounds (~
105 – 106) are screened to assess for biological activity against a target. This has led to the
identification of drug-like and lead-like compounds with desirable pharmacological and biological
activity. Although HTS uses a large compound library, it only samples a small fraction of the
chemical space of small molecules. FBDD is a powerful tool that has recently emerged and has
been crucial in the small-molecule drug design process. Fragments are low-molecular-weight (<
300 Da) compounds that usually have low binding affinity for the target [89-91]. These fragments
are then modified, grown, and linked together to create a lead compound with high affinity and
selectivity (Fig. 1.11). Compared to HTS, FBDD has the advantage of sampling a much wider
chemical space, thus producing a significantly higher hit rate [91].

1.7 Molecular Docking
Molecular docking has become an increasingly important computational tool that is vital
to drug discovery. The goal of molecular docking is to predict the ligand binding mode to a protein
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structure. Many variables play a role in the prediction of ligand-protein interactions, which include
the flexibility of the ligand and target, electrostatic interactions, van der Waals interactions,
formation of HBs, and presence of water molecules [92, 93]. The sum of these interactions is
determined by a scoring function, which estimates binding affinities between the ligand and target
(Fig. 1.11) [94]. Numerous molecular docking programs have been developed for both academic
and commercial use that utilize different algorithms for ligand docking. Some of these programs
include AutoDock [95], DOCK [96], Glide [97], and SwissDock [98].

1.8 X-ray Crystallography
X-ray crystallography is a powerful technique that allows researchers to analyze the threedimensional structure of macromolecules such as proteins. X-ray crystallography is a multifaceted
technique involving large scale expression of the protein of interest, purifying the protein, and
setting up multiple crystallization trials in order to find suitable crystals for X-ray diffraction.
Ultimately, solved protein structures are deposited into the Protein Data Bank (PDB), which
currently contains over 100,000 protein structures solved using X-ray crystallography (Fig. 1.12)
[99]. X-ray crystallography is an indispensable technique in FBDD and lead optimization.
Analyzing the three-dimensional structure of a protein target bound by a ligand provides valuable
insights into the interactions that drive binding affinity, as well as highlighting the potential areas
for modification of the ligand in an effort to increase activity. This approach is known as structurebased drug design (SBDD) since it combines the power of many techniques such as X-ray
crystallography, nuclear magnetic resonance (NMR), medicinal chemistry, and FBDD to guide
and assist drug development [100].

14

1.9 Structure-Based Drug Design Targeting -Lactamases
FBDD, molecular docking, and SBDD have all been used to discover novel inhibitors
against serine -lactamases and MBLs [101]. One notable example of this success is against the
class A -lactamase, CTX-M-9 [102]. For CTX-M-9, FBDD led to the discovery of a tetrazolebased fragment inhibitor with a Ki of 21 M. A complex crystal structure of this compound in the
active site of CTX-M-9 revealed two binding hot spots that could be exploited to increase affinity.
The fragment was grown by adding substituents, and ultimately the affinity was improved more
than 200-fold against CTX-M-9 (Fig. 1.13) [102].

1.10 Conclusions
Bacterial antibiotic resistance is quickly becoming a global health threat. A common
mechanism of bacterial antibiotic resistance is the production of -lactamase enzymes that can
deactivate the -lactam antibiotics (e.g., penicillins, cephalosporins, monobactams, and
carbapenems). There are four classes of -lactamases that differ from one another based on their
amino acid sequence and mechanism of action. Class A, C, and D -lactamases are enzymes that
use an active site serine residue to perform -lactam hydrolysis, whereas class B -lactamases are
metalloenzymes that use one or two zinc ions to catalyze the same reaction. One of the most
alarming resistance trends is the emergence of carbapenemases that can deactivate virtually all lactam antibiotics. Carbapenemases such as KPC-2 (class A), NDM-1/VIM-2 (class B), and OXA48 (class D) have been reported in numerous Gram-negative pathogens. To address the issue of
carbapenemases, inhibitors such as avibactam and vaborbactam were developed; however, these
inhibitors fall short since they are active only against serine carbapenemases and not MBLs. This
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dissertation will expand on the understanding of serine -lactamase catalysis and inhibition
(Chapters 2, 3, and 4). Also presented will be the effort of finding a dual action serine
carbapenemase and MBL inhibitor using molecular docking, FBDD, and structure-activity
relationship (SAR) studies (Chapter 5).

1.11 Note to Reader #1
Figure 1.1 in this chapter was previously published by [12] Lewis, K. (2013). Platforms
for antibiotic discovery. Nature Reviews Drug Discovery, 12(5), 371-387 and has been reproduced
with permission (See Appendix 1).
Figure 1.2 in this chapter was previously published by [12] Lewis, K. (2013). Platforms
for antibiotic discovery. Nature Reviews Drug Discovery, 12(5), 371-387 and has been reproduced
with permission (See Appendix 1).
Figure 1.3 in this chapter was previously published by [57] Palzkill, T. (2012). Metallo-lactamase structure and function. Annals of the New York Academy of Sciences, 1277(1), 91-104
and has been reproduced with permission (See Appendix 1).
Figure 1.4 in this chapter was previously published by [25] Wilke, M. S., Lovering, A. L.,
& Strynadka, N. C. (2005). -Lactam antibiotic resistance: A current structural perspective.
Current Opinion in Microbiology, 8(5), 525-533 and has been reproduced with permission (See
Appendix 1).
Figure 1.6 in this chapter was previously published by [39] Vandavasi, V. G., Weiss, K.
L., Cooper, J. B., Erskine, P. T., Tomanicek, S. J., Ostermann, A., Coates, L. (2016). Exploring
the mechanism of -lactam ring protonation in the class A -lactamase acylation mechanism using
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neutron and X-ray crystallography. Journal of Medicinal Chemistry, 59(1), 474-479 and has been
reproduced with permission (See Appendix 1).
Figure 1.7 in this chapter was previously published by [57] Palzkill, T. (2012). Metallo-lactamase structure and function. Annals of the New York Academy of Sciences, 1277(1), 91-104
and has been reproduced with permission (See Appendix 1).
Figure 1.8 in this chapter was previously published by [57] Palzkill, T. (2012). Metallo-lactamase structure and function. Annals of the New York Academy of Sciences, 1277(1), 91-104
and has been reproduced with permission (See Appendix 1).
Figure 1.9 in this chapter was previously published by [60] Papp-Wallace, K. M.,
Endimiani, A., Taracila, M. A., & Bonomo, R. A. (2011). Carbapenems: past, present, and future.
Antimicrobial Agents and Chemotherapy, 55(11), 4943-4960 and has been reproduced with
permission (See Appendix 1).
Figure 1.12 in this chapter was previously published by [99] Shi, Y. (2014). A glimpse of
structural biology through X-ray crystallography. Cell, 159(5), 995-1014 and has been reproduced
with permission (See Appendix 1).
Figure 1.13 in this chapter was previously published by [102] Nichols, D. A., Jaishankar,
P., Larson, W., Smith, E., Liu, G., Beyrouthy, R., Chen, Y. (2012). Structure-based design of
potent and ligand-efficient inhibitors of CTX-M class A -lactamase. Journal of Medicinal
Chemistry, 55(5), 2163-2172 and has been reproduced with permission (See Appendix 1).
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Figure 1.1. Antibiotic targets. Targets for antibiotics in bacteria include DNA
synthesis, protein synthesis, cell wall synthesis, and folic acid metabolism. Adapted
with permission from [12]. See Appendix 1.
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Figure 1.2. Mechanisms of antibiotic resistance. The main mechanisms of antibiotic
resistance include enzyme inactivation or modification, target modification, decreased
drug penetration, increased drug efflux, and bypass of pathways. Adapted with
permission from [12]. See Appendix 1.
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Figure 1.3. Classes of ‐lactam antibiotics. (A) Core structure of penicillins.
(B) Core structure of cephalosporins. (C) Core structure of monobactams. (D)
Core structure of carbapenems. Different R‐groups distinguish various
penicillin, cephalosporin, monobactam, and carbapenem derivatives. Adapted
with permission from [57]. See Appendix 1.
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Figure 1.4. Strategies for -lactam resistance. -Lactam resistance can be
mediated by -lactamases, alterations in PBPs, and efflux pumps. Adapted with
permission from [25]. See Appendix 1.
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Figure 1.5. Ambler classification scheme of -lactamases. Schematic diagram of Ambler
classification system.
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Figure 1.6. Catalytic mechanism of class A -lactamases. Class A -lactamase catalysis proceeds
through a two-step acylation/deacylation reaction that leads to -lactam hydrolysis. The acylation reaction
initiates with the formation of a pre-covalent substrate complex (1). General base-catalyzed nucleophilic
attack on the -lactam carbonyl by Ser70’s hydroxyl group proceeds through a tetrahedral intermediate
(2) to a transiently stable acyl–enzyme adduct (3). In the deacylation phase, the acyl–enzyme adduct (3)
undergoes general base-catalyzed attack by a hydrolytic water molecule to form a second tetrahedral
intermediate (4), which collapses to a post-covalent product complex (5), from which the hydrolyzed lactam product is released. Adapted with permission from [39]. See Appendix 1.

23

Figure 1.7. Zinc coordinating residues of MBL subclasses. (A) Subclass B1, (B) subclass B2,
and (C) subclass B3. Adapted with permission from [57]. See Appendix 1.
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Figure 1.8. Catalytic mechanism of subclass B1 and B3 MBLs. The zinc ions are labeled and
interactions are shown with dashed lines. (A) Cephalosporin substrate binds to the active site and
interacts with both Zn1 and Zn2 via the carbonyl oxygen and carboxyl groups, respectively. The bound
hydroxide is positioned to attack the carbonyl carbon of the substrate. (B) Anionic intermediate bound
in the active site via stabilizing interactions provided by Zn2. Adapted with permission from [57]. See
Appendix 1.
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Figure 1.9. Comparison of carbapenems to penicillins and cephalosporins. (A) A 1--methyl (red)
prevents breakdown from the renal enzyme dehydropeptidase I (DHP-I). (B) The pyrrolidine ring
(red) increases stability and spectrum against multiple bacteria. (C) Penicillin, cephalosporin, and
carbapenem chemical structures. Carbapenem has a five-membered ring, as does penicillin, but a
carbon is located at position 1 instead of a sulfur. (D) All carbapenems have a hydroxyethyl group at
C-6. (E) The R configuration of the hydroxyethyl increases the -lactam's potency. (F) The transconfiguration of carbapenems at the C-5—C-6 bond increases their potency and stability against lactamases as compared to penicillins and cephalosporins, which have a cis-configuration. Adapted
with permission from [60]. See Appendix 1.

26

Clavulanic acid

Sulbactam

Avibactam

Tazobactam

Vaborbactam

Figure 1.10. Commonly used BLIs. -Lactam (clavulanic acid, sulbactam, and tazobactam) and
non--lactam-based (avibactam and vaborbactam) BLIs.
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Figure 1.11. General scheme for FBDD. In FBDD, a library of small
molecules is placed into the binding site of a target using molecular
docking. A scoring function ranks the molecules, and compounds are
purchased or synthesized for biochemical testing. Low affinity
inhibitors are selected and false positives are removed. The low
affinity inhibitors are modified and linked together to create an
inhibitor with high affinity for the target.
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Figure 1.12. Growing number of protein structures deposited in the
PDB. (A) The number of protein structures in the PDB are rapidly growing
every year. As of 2017, there are over 100,000 protein structures found in
the PDB. (B) Membrane proteins account for less than 5% of all deposited
protein structures. Adapted with permission from [99]. See Appendix 1.
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Figure 1.13. Structure-based design of a CTX-M-9 BLI. Structure-based design was used in the
development of a tetrazole-containing inhibitor of CTX-M-9, displaying nanomolar potency and cellbased activity. Adapted with permission from [102]. See Appendix 1.
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Chapter 2:
Molecular Basis of Substrate Recognition and Product Release by the Klebsiella
pneumoniae Carbapenemase (KPC-2)

2.1 Overview
CRE are resistant to many β-lactam antibiotics, thanks in part to the production of the KPC2 class A -lactamase. Here, I present the first product complex crystal structures of KPC-2 with
β-lactam antibiotics containing hydrolyzed cefotaxime (cephalosporin) and hydrolyzed faropenem
(penem). These complex crystal structures provide experimental insights into the substrate
recognition by KPC-2 and its unique broad-spectrum -lactamase activity. These structures also
represent the first product complexes for a wild-type (WT) serine β-lactamase, which helped
elucidate the product release mechanism of these enzymes.

2.2 Introduction
The KPC-2 class A β-lactamase poses a serious threat to nearly all β-lactam antibiotics [1].
KPC was first identified in North Carolina in 1996, and has since spread to many other countries
[2]. Although initially identified in K. pneumoniae, KPC has also been discovered in other Gramnegative bacterial pathogens, mainly belonging to the Enterobacteriaceae family [3]. The blaKPC
gene encodes a 293 residue protein with 23 variants (KPC-2 through KPC-24) that differ from one
another by only one or two amino acid changes [4]. KPC-2 is the most prevalent carbapenemase
in the United States, and it has been termed the “versatile β-lactamase” due to its large and shallow
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active site, permitting the efficient hydrolysis of virtually all β-lactam antibiotics [5]. However,
the question still remains as to what specific interactions between β-lactams and the KPC-2 active
site allow for such a broad substrate profile [6, 7]. The reaction catalyzed by class A β-lactamases
proceeds through two steps: acylation and deacylation [3]. The nucleophilic attack of Ser70 on the
substrate β-lactam ring results in a covalent acyl–enzyme complex. Subsequently, the catalytic
water is activated by Glu166 and cleaves the acyl–enzyme linkage, leading to the formation of the
hydrolyzed product. One common way to capture a β-lactam complex along the reaction pathway
of class A β-lactamases is to mutate a key catalytic residue, such as Ser70 or Glu166, to
accommodate the newly generated carboxylate group [8]. The complex structures presented herein
represent the first product complexes using a WT serine β-lactamase with all native active site
residues intact. This provides an accurate picture of the protein microenvironment that is
responsible for catalysis, particularly during product release.

2.3 Results and Discussion
I attempted to obtain complex crystal structures with a variety of β-lactams, including the
cephalosporins ceftazidime, cefotaxime, cefoxitin, and nitrocefin; the penicillins ampicillin,
cloxacillin, and benzylpenicillin; the carbapenems biapenem, imipenem, and meropenem; the
penem faropenem; and the monobactam aztreonam. Ultimately, I was able to obtain two crystal
structures of cefotaxime and faropenem as hydrolyzed products in the active site of KPC-2 (Fig.
2.1). As discussed herein, the unique features of KPC-2, and the two substrates, may have
contributed to the capture of these two complexes.
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2.3.1 Product complex with cefotaxime
KPC-2 was crystallized in the space group P22121 with one copy of KPC-2 in the
asymmetric unit (Table 2.1). KPC-2 crystals routinely diffracted to 1.15–1.5 Å resolution. The
apo-structure is similar to that of previously determined KPC-2 models crystallized in different
space groups (Fig. 2.2) [9, 10]. The product complex structure with cefotaxime was determined to
1.45 Å resolution with final Rwork and Rfree values of 16.8% and 21.2%, respectively. The electron
density for the product is well-defined in the active site as seen in the unbiased Fo–Fc map (Fig.
2.3A). The occupancy value of the hydrolyzed product was refined to 0.86. There are some
differences in the active site when comparing the cefotaxime complex structure to the apoenzyme,
mainly with residues Ser70, Trp105, and Leu167 (Fig. 2.3B) because of interactions between the
hydrolyzed product and the enzyme. The complex structure illustrates how the bulky oxyimino
group of third-generation cephalosporins and the newly generated carboxylate group of the product
are accommodated by the KPC-2 active site. It represents the first experimental structure of KPC2 in complex with a clinically used β-lactam antibiotic, and sheds new light on the extensive
interactions between cefotaxime and the active site residues. The C4 carboxylate group resides in
a subpocket formed by Thr235, Gly236, Thr237, and Ser130. This region is highly conserved in
serine β-lactamases, and PBPs, as shown by previous crystallographic studies of these enzymes
and their complexes [11, 12]. The six-membered dihydrothiazine group of the hydrolyzed product
forms a pi–pi stacking interaction with Trp105, which has been demonstrated to be important in
-lactam substrate recognition [13]. The interactions with the substrate also result in a single
conformation of Trp105, which is observed to have two conformations in the apoenzyme (Fig.
2.3B). Meanwhile, cefotaxime’s acylamide side chain is nestled in a pocket formed by Thr237,
Cys238, Gly239, Leu167, and Asn170 (Fig. 2.3A). The aminothiazole moiety forms extensive
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nonpolar interactions with Leu167, in addition to van der Waals contacts with Asn170, Cys238,
and Gly239. In particular, compared with the apo-structure, the alkyl side chain of Leu167 moves
closer to interact with the substrate (Fig. 2.3B). In comparison, the oxyimino group is largely
solvent exposed and establishes relatively few interactions with the protein, mainly with
Thr237C2 and Gly239C (Fig. 2.3A).
As the first product complex with a WT serine β-lactamase, this KPC-2 structure also
captures structural features not seen in previous β-lactamase complexes, particularly concerning
the conformations of Ser70, Lys73, Ser130, and the substrate carbonyl group. In class A βlactamases, Ser70 carries out nucleophilic attack on the β-lactam ring of the substrate [14]. In the
apoenzyme, Ser70 forms a HB with Lys73, which has been suggested as a potential base in the
acylation step [15, 16]. In my structure, the presence of the newly generated C8 carboxylate group,
a result of the catalytic water’s attack on the carbon atom of the acyl–enzyme carbonyl group,
causes Ser70 to adopt a conformation that places its side chain hydroxyl group in the oxyanion
hole formed by the backbone amide groups of Ser70 and Thr237, and previously occupied by the
carbonyl oxygen of the acyl–enzyme intermediate (Fig. 2.3B, D). This conformational change
abolishes the HB between Ser70 and Lys73 and establishes a new HB between Ser70 and the
substrate ring nitrogen, an interaction not observed at any other stage of the reaction (Fig. 2.3B).
Meanwhile, the side chain of Lys73 moves to form a HB with Ser130.
Unlike most previous β-lactamase structures, Ser130 adopts two conformations (Fig. 2.3A)
[17]. Conformation 1 maintains a weak HB with Lys73, is in close proximity to the ring nitrogen,
and is the conformation usually observed in class A β-lactamases [18]; conformation 2 swings
closer to Lys234 and the substrate C4 carboxylate group, establishing more favorable HBs with
the latter two functional groups. Additionally, the amide nitrogen of the cefotaxime product forms
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a weak HB with the backbone carbonyl group of Thr237 (Fig. 2.3A). In a previous CTX-M-14
E166A complex structure with a ruthenocene-conjugated penicillin (PDB ID code: 4XXR) [19],
Ser130 adopts conformation 1 and serves as a HB acceptor and donor in its interactions with the
protonated ring nitrogen and a neutral Lys73, respectively (Fig. 2.3C). In my current structure,
Lys73 appears to be protonated and is within HB distance (2.6–2.9 Å) to three HB acceptors,
including Ser130O, Asn132O1, and the substrate C8 carboxylate group. In comparison, the
distance between Lys73N and Ser130O of conformation 1 is 3.1 Å, suggesting a weak HB
contact. Ser130O of conformation 1 is also too far away from the ring nitrogen (3.5 Å) for a HB.
The weakened interactions between Ser130 and Lys73, or the substrate ring nitrogen, likely
contribute to Ser130’s adoption of conformation 2, which highlights Ser130’s role in binding the
substrate carboxylate group. Taken together, the alternative conformations of Ser70, Lys73, and
Ser130 underscore the important noncatalytic roles these residues play in the product release
process.
Previous studies have suggested that steric clash and electrostatic repulsion caused by the
newly generated C8 carboxylate group of cefotaxime is responsible for the expulsion of the
hydrolyzed product from the active site [8, 20]. My structure supports this hypothesis and provides
important new structural details on potential unfavorable interactions that lead to product
expulsion. In my structure, possible clashes between the C8 carboxylate group and Ser70 are
alleviated by Ser70’s adoption of an alternative, and likely high energy, conformation with a side
chain χ1 angle of 10°, in comparison to the more favorable 60° in Ser70’s usual conformation. In
the complex structure of the AmpC class C β-lactamase S64G mutant with hydrolyzed cephalothin
(PDB ID code: 1KVL), the electrostatic repulsion between the C8 and C4 carboxylate groups
caused the C4 carboxylate group to move out of the active site, resulting from the rotation of the
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dihydrothiazine ring, and leading to an increase in distance between these two negatively charged
groups [21]. In my structure, the C4 carboxylate group remains in the active site, albeit in a likely
less stable state due to the electrostatic repulsion. Although the C8 carboxylate group can establish
new interactions with Lys73, these contacts are accompanied by the loss of HBs between the
substrate and the oxyanion hole, between Ser70 and Lys73, and for class A β-lactamases, by
possible additional repulsion between the C8 carboxylate group and Glu166 (Fig. 2.3B). Another
unique feature of the product complex is the lack of a HB between the substrate amide group with
Asn132, even though the substrate amide group forms a HB with the backbone O atom of Thr237
(Fig. 2.3A). The HB with Asn132 is present in nearly all complex structures of serine β-lactamases
with β-lactams containing the amide group, including the aforementioned CTX-M-14 E166A
product complex (PDB ID code: 4XXR) and a Toho-1 E166A/cefotaxime complex (PDB ID code:
1IYO) structure (Fig. 2.3D) [8, 19, 22]. Instead, in this structure, the carbonyl oxygen is pushed
out of the active site and exposed to solvent (Fig. 2.3C, D). The loss of the HB between the ligand
amide group and Asn132 further suggests that the interactions between the product and the enzyme
are less favorable compared with the Michaelis substrate complex, which may facilitate substrate
turnover during catalysis.
I observed an additional molecule of hydrolyzed cefotaxime near the active site, with a
refined occupancy value of 0.72 (Fig. 2.4). This molecule did not make as many interactions in the
active site as seen in the other hydrolyzed molecule. There is a HB between Lys270 and the C4
carboxylate group of the second hydrolyzed product, as well as a HB between the aminothiazole
group of the first hydrolyzed product and the C4 carboxylate of the second hydrolyzed product. I
believe that the presence of this second hydrolyzed product is a crystal-packing artifact and does
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not play a role in catalysis. Though interestingly, it may have partially stabilized the first
hydrolyzed product inside the active site in the crystal.

2.3.2 Product complex with faropenem
Faropenem belongs to the penem class of β-lactam antibiotics (Fig. 2.1). Penems share the
structural characteristics of both penicillins and cephalosporins [24]. Like carbapenems, penems
have a hydroxyethyl group attached to the β-lactam ring in the trans-configuration that provides
stability against many serine β-lactamases [5]. I captured a single hydrolyzed molecule of
faropenem in the active site of KPC-2 (Fig. 2.5A). The complex structure with faropenem was
solved to 1.40 Å resolution with final Rwork and Rfree values of 15.0% and 18.8%, respectively
(Table 2.1). The occupancy value of the hydrolyzed product was refined to 0.84. Compared to the
product complex with cefotaxime, the hydrolyzed faropenem induces similar conformations of
Ser70 and Trp105, and makes many similar interactions in the active site (Fig. 2.5B). For instance,
the C7 carboxylate group, which is analogous to the cefotaxime C8 carboxylate group, forms HBs
with Ser130, Thr235, and Thr237; conformation 2 of Ser130 forms a HB with the C3 carboxylate
group, which is analogous to the cefotaxime C4 carboxylate group (Fig. 2.5A). Unlike the
cefotaxime complex, the ring nitrogen forms a HB with conformation 1 of Ser130, rather than
Ser70, likely as a result of the smaller five-membered dihydrothiazole ring in faropenem, in
comparison to the six-membered dihydrothiazine ring in cefotaxime.
One important observation in this faropenem structure is the conformation of the
hydroxyethyl side chain. The faropenem structure shows that the hydroxyethyl side chain has
undergone rotation, abolishing its interaction with Asn132. Previous studies have shown that, in
noncarbapenemases such as SED-1 (PDB ID code: 3BFF), the hydroxyethyl group of carbapenems
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forms a HB with Asn132 and the catalytic water, consequently deactivating the catalytic water
molecule and leaving these enzymes unable to hydrolyze the acyl–enzyme linkage [23]. However,
in carbapenemases like KPC-2, the active site is enlarged, permitting rotation of the hydroxyethyl
group, thus abolishing its interaction with Asn132 and allowing hydrolysis of carbapenem
antibiotics (Fig. 2.5C) [23, 25-27]. Importantly, in the current structure, Leu167 is in favorable
van der Waal contact with the methyl group of faropenem’s hydroxyethyl moiety, suggesting that
Leu167 may play a catalytic role in inducing the rotation of this side chain group to facilitate
carbapenem hydrolysis. Although position 167 is not well-conserved among class A β-lactamases,
it appears that a leucine is conserved at this position in class A carbapenemases [11]. When
comparing the cefotaxime and faropenem product complexes, movements are observed in Val103,
the Pro104-Trp105 loop, and Leu167 (Fig. 2.5D). These movements are likely due to the different
interactions between the faropenem tetrahydrofuran group and Trp105, and between the
cefotaxime aminothiazole group and Leu167. In addition, because of the different chiralities of the
C6/C7 atoms linked to the C7/C8 carboxylate group, the newly generated carboxylate group is
positioned slightly differently between the two product complexes. Taken together, these findings
highlight the flexibility of the KPC-2 active site for accommodating a variety of β-lactam side
chains.

2.3.3 Unique KPC-2 structural features for inhibitor discovery
Despite extensive structural studies of numerous serine β-lactamases, my structures
represent the only product complexes with a WT enzyme. All previous studies relied on mutations,
such as S70G, to stabilize the interactions between the product and the enzyme active site [8]. The
many unfavorable features of the enzyme–product contacts have made it difficult to capture such
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complexes with WT enzymes, even for KPC-2, as demonstrated by the failures to obtain similar
complexes using many other β-lactam antibiotics. The successes with my current two complexes
may have been due to the particular side chains of these two substrates, and some unique properties
of carbapenemases such as KPC-2. In comparison to other β-lactam compounds, the oxyimino side
chain of cefotaxime and the tetrahydrofuran side group of faropenem enhance the interactions
between the product and KPC-2, and avoids excessive bulkiness that may cause steric clashes with
protein residues in a crystal-packing environment. More importantly, compared with narrowspectrum β-lactamases (e.g., TEM-1) and ESBLs (e.g., CTX-M-14), KPC-2 and other class A
carbapenemases contain several key features and residues that result in an enlarged active site,
including a Cys69–Cys238 disulfide bond, Leu167, Pro104, and Trp105. Movements of Ser70 and
Asn170 are also observed in the KPC-2 structure. There is a larger distance between Ser70 and
Asn170 in KPC-2 as compared to that in noncarbapenemases like TEM-1 and CTX-M-14, which
may facilitate rotation of the hydroxyethyl group of carbapenems that endows them with stability
against hydrolysis by many serine -lactamases [9]. Importantly, the KPC-2 active site also
appears to be more hydrophobic, with larger nonpolar surfaces provided by Pro104, Trp105,
Leu167, and Val240, in comparison to their counterparts Glu104, Tyr105, Pro167, and Asp240 in
TEM-1 (Fig. 2.6A) and Asn104, Tyr105, Pro167, and Asp240 in CTX-M-14 (Fig. 2.6B). These
features may allow KPC-2 to bind to a wide range of β-lactam substrates with a relatively open
active site. They are mirrored by similar observations in MBLs that also harbor expanded active
sites with a large number of hydrophobic residues [28]. Such features may enable carbapenemases
to hydrolyze nearly all β-lactam antibiotics, while also exposing a weakness that can facilitate the
engineering of high affinity inhibitors against these enzymes.
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2.4 Conclusions
In this work, I present the first crystal structures of the KPC-2 class A β-lactamase in
complex with two clinically used β-lactam antibiotics, cefotaxime and faropenem. The structures
underscore the role of the enlarged and shallow active site in accommodating the bulky cefotaxime
oxyimino side chain, the rotation of faropenem’s 6α-1R-hydroxyethyl group and, particularly,
Leu167’s critical contribution in catalysis. These structures demonstrate how alternative
conformations of Ser70 and Lys73 facilitate product release and capture unique substrate
conformations at this important milestone of the reaction. Additionally, these structures highlight
the increased druggability of the KPC-2 active site, which provides an evolutionary advantage for
the enzyme’s catalytic versatility, but also an opportunity for drug discovery.

2.5 Materials and Methods

2.5.1 Cloning, expression, and purification of KPC-2
The KPC-2 gene sequence (residues 25-293) was cloned into the pET-GST vector between
NdeI and BstBI restriction sites as an N-terminal His-tagged fusion protein. The construct was
verified by DNA sequencing and transformed into BL21 (DE3) competent cells for protein
expression. For His-tagged KPC-2, bacteria were grown overnight at 30 °C with shaking in 50 mL
LB broth supplemented with 50 g/mL kanamycin. Two liters of LB broth supplemented with 50
g/mL kanamycin, 200 mM sorbitol, and 5 mM betaine were each inoculated with 10 mL of
overnight bacterial culture and grown at 37 °C until reaching an OD600=0.6-0.8. Protein expression
was then initiated by the addition of 0.5 mM IPTG followed by growth for 16 hrs at 20 °C. Cells
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were pelleted by centrifugation and stored at -80 °C until further use. The His-tagged KPC-2 was
purified by nickel affinity chromatography and gel filtration. Briefly, the cell pellets were thawed
and re-suspended in 40 mL of buffer A (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 20 mM
imidazole) with one complete protease inhibitor cocktail tablet (Roche) and disrupted by
sonication, followed by centrifugation at 45,000 RPM to clarify the lysate. After centrifugation,
the supernatant was filtered before loading onto a 5 mL HisTrap HP affinity column (GE
Healthcare Life Sciences, USA) pre-equilibrated with buffer A. His-tagged KPC-2 was eluted by
a linear imidazole gradient (20 mM to 500 mM). Fractions were analyzed by SDS-PAGE.
Fractions containing His-tagged KPC-2 were pooled and loaded onto a Superdex75 16/60 gel
filtration column (GE Healthcare Life Sciences) pre-equilibrated with 20 mM Tris-HCl pH 8.0,
300 mM NaCl. Protein concentration was determined by absorbance at 280 nm using an extinction
coefficient of 39,545. SDSPAGE analysis indicated that the eluted protein was more than 95%
pure. The protein containing fractions were pooled and concentrated to 10-20 mg/mL. The protein
was aliquoted and then flash frozen in liquid nitrogen, and stored at -80 °C.

2.5.2 Crystallization and soaking experiments
Crystals of His-tagged KPC-2 were grown at 20 °C using hanging-drop vapor diffusion.
Protein solutions (10-20 mg/ml) in 20 mM Tris-HCl pH 8.0, 300 mM NaCl were mixed 1:2 (v/v)
with a reservoir solution containing 2 M ammonium sulfate and 5% (v/v) ethanol. Droplets (1.5
L) were microseeded with 0.5 L of diluted seed stock. Crystals typically began to form within
two weeks. To obtain the ligand bound structures, KPC-2 crystals were soaked in a solution
containing 1.44 M sodium citrate and 30 mM cefotaxime/faropenem for 30 minutes. The soaked
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crystals were cryo-protected in a solution containing 1.15 M sodium citrate, 20% (v/v) glycerol
and flash-frozen in liquid nitrogen.
2.5.3 Data collection and structure determinations
Data for the KPC-2 complex structures were collected using beamlines 22-ID-D and 23ID-D at the Advanced Photon Source (APS), Argonne, Illinois. Diffraction data were indexed and
integrated with iMosflm [29] and scaled with SCALA from the CCP4 suite [30]. Phasing was
performed using molecular replacement with the program Phaser [31], with the truncated KPC-2
structure (PDB ID code: 3C5A). Structure refinement was performed using phenix.refine [32] and
model building in WinCoot [33]. The unbiased Fo-Fc electron density maps were generated prior
to refinement with compound. The program eLBOW [34] in Phenix was used to obtain geometry
restraint information. The final model qualities were assessed using MolProbity [35]. Figures were
generated in PyMOL 1.3 (Schrödinger) [36] in which structural alignments were generated using
pairwise scores. LigPlot+ v.1.4.5 was used to generate ligand-protein interactions [37].

2.6 Note to Reader #1
Portions of this chapter have been reproduced from Pemberton, O. A., Zhang, X., & Chen,
Y. (2017). Molecular basis of substrate recognition and product release by the Klebsiella
pneumoniae carbapenemase (KPC-2). Journal of Medicinal Chemistry, 60(8), 3525-3530 with
permission of the 2017 American Chemical Society (see Appendix 1).
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Figure 2.1. Chemical structures of intact and hydrolyzed cephalosporin and penem -lactam
antibiotics. Structures of cephalosporins (cephalothin, cefotaxime), carbapenem (meropenem), and
penem (faropenem) β-lactam antibiotics.
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Figure 2.2. Superimposition of apo KPC-2 structures. Green (PDB ID code: 3C5A),
cyan (PDB ID code: 2OV5), purple (PDB ID code: 3DW0), current apo-structure (yellow).
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Figure 2.3. KPC-2 cefotaxime product complex. The protein and ligand of
the complex are shown in white and yellow, respectively. HBs are shown as
black dashed lines. (A) Unbiased Fo–Fc electron density map (gray) of
hydrolyzed cefotaxime contoured to 2σ. (B) Superimposition of KPC-2 product
complex onto apoprotein (green) with details showing the interactions
involving Ser70, Lys73, the cefotaxime ring nitrogen, and the newly formed
C8 carboxylate group. PyMOL alignment RMSD = 0.153 Å over 272 residues.
(C) Superimposition of KPC-2 product complex and CTX-M-14 E166A
penilloate product complex with a ruthenocene-conjugated penicillin (green,
with residues unique to CTX-M-14 E166A labeled in green) in stereo view.
The ruthenium atom is shown as a gray sphere. PyMOL alignment RMSD =
0.617 Å over 272 residues. (D) Superimposition of KPC-2 product complex
with Toho-1 E166A acyl–enzyme complex with cefotaxime (green, with
residues unique to Toho-1 E166A labeled in green). PyMOL alignment RMSD
= 0.602 Å over 264 residues.
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Figure 2.4. Two molecules of hydrolyzed cefotaxime in the KPC-2 active site. Hydrolyzed
cefotaxime 1 and 2 (yellow) are shown in the active site of KPC-2. The unbiased Fo-Fc electron density
map (gray) is contoured at 2 σ. HBs are shown as black dashed lines. The refined occupancy values
of cefotaxime 1 and 2 are 0.86 and 0.72, respectively.
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Figure 2.5. KPC-2 faropenem product complex. The protein and ligand of
the faropenem product complex are shown in white and yellow, respectively.
HBs are shown as black dashed lines. (A) The unbiased Fo–Fc electron density
map (gray) of hydrolyzed faropenem contoured at 2σ. (B) Superimposition of
KPC-2 faropenem complex onto apoprotein (green) with details showing the
interactions involving Ser70, Lys73, and the newly formed faropenem C7
carboxylate group. PyMOL alignment RMSD = 0.141 Å over 270 residues. (C)
Superimposition of KPC-2 product complex with SED-1 faropenem acyl–
enzyme (green) in stereo view. The deacylation water (red sphere) from SED-1
is shown making interactions with Glu166 and the hydroxyethyl group of
faropenem. PyMOL alignment RMSD = 0.555 Å over 262 residues. (D)
Superimposition of faropenem/cefotaxime product complexes, showing the
movement of the Pro104-Trp105 loop and alternative conformations for
Val103 and Leu167 (KPC-2/faropenem: white/yellow; KPC-2/cefotaxime:
green). PyMOL alignment RMSD = 0.101 Å over 270 residues.
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Figure 2.6. Comparison of KPC-2 active site with the narrow-spectrum βlactamase TEM-1 and the ESBL CTX-M-14. (A) KPC-2 complexed with
cefotaxime superimposed onto TEM-1 (KPC-2: white, TEM-1: green,
cefotaxime: yellow). (B) KPC-2 complexed with faropenem superimposed
onto CTX-M-14 (KPC-2: white, CTX-M-14: green, faropenem: yellow).
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A

B

Figure 2.7. Molecular interactions of hydrolyzed cefotaxime and faropenem in the active site of KPC-2 from
LigPlot+. (A) Hydrolyzed cefotaxime and (B) hydrolyzed faropenem.
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Table 2.1. X-ray data collection and refinement statistics for KPC-2 apo and hydrolyzed products
Structure

Apo KPC-2

KPC-2 with Hydrolyzed
Cefotaxime

KPC-2 with Hydrolyzed
Faropenem

P22121

P22121

P22121

a, b, c (Å)

55.80, 60.20, 78.62

56.93, 58.78, 76.84

57.14, 59.13, 77.38

 (°)

90, 90, 90

90, 90, 90

90, 90, 90

45.50-1.15 (1.21-1.15)

45.74-1.45 (1.53-1.45)

46.98-1.40 (1.48-1.40)

93,824 (12,888)

45,653 (6,335)

52,337 (7,543)

3.073 (36.2)

12.7 (68.4)

9.5 (88.8)

I/σ(I)

11.0 (2.0)

9.1 (2.3)

9.9 (2.2)

Completeness (%)

99.1 (94.4)

98.5 (95.6)

99.9 (100)

6.5 (3.3)

6.5 (5.3)

7.0 (6.6)

Resolution (Å)

32.14-1.15

40.89-1.45

36.30-1.40

Rwork (%)

12.2 (26.1)

16.8 (31.9)

15.0 (25.7)

Rfree (%)

13.9 (26.9)

21.2 (34.5)

18.8 (27.5)

Protein

2136

2090

2109

Ligand/Ion
Water
B-factors (Å2)

26
350

60
255

26
223

protein

14.08

15.58

22.42

ligand/ion

28.32

22.02

37.11

water

31.96

30.91

36.78

Bond lengths (Å)

0.009

0.005

0.005

Bond angles (°)

1.08

0.85

0.81

favored (%)

98.88

98.88

98.87

allowed (%)

1.12

1.12

1.13

Data Collection

Space group
Cell dimensions

Resolution (Å)
No. of unique reflections
Rmerge (%)

Multiplicity

Refinement

No. atoms

RMS deviations

Ramachandran plot

outliers (%)
PDB code

0

0

0

5UL8

5UJ3

5UJ4

*Statistics for the highest-resolution shell are shown in parentheses
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Table 2.2. Hydrolyzed products hydrogen bond distances within
KPC-2. HB distances between KPC-2 active site residues and
hydrolyzed cefotaxime and faropenem products calculated from LigPlot+

Interactions of KPC-2 with
hydrolyzed cefotaxime
Ser70 OG – Cefotaxime N23
Lys73 NZ - Cefotaxime O21
Ser130 OG – Cefotaxime O21
Ser130 OG – Cefotaxime O27
Thr235 OG1 - Cefotaxime O27
Thr237 OG1 – Cefotaxime O26
Thr237 O – Cefotaxime N07

Distance (Å)

Interactions of KPC-2 with
hydrolyzed faropenem
Ser70 OG – Faropenem O19
Lys73 NZ – Faropenem O19
Lys73 NZ – Faropenem O20
Ser130 OG – Faropenem N06
Ser130 OG – Faropenem O09
Asn 132 ND2 – Faropenem O20
Thr235 OG1 – Faropenem O09
Thr237 OG1 – Faropenem O10

Distance (Å)

2.95
2.58
3.00
2.98
2.70
2.55
3.21

2.63
3.16
3.06
3.10
3.08
2.95
2.64
2.52
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Chapter 3:
Studying Proton Transfer in the Mechanism and Inhibition of Serine Lactamase Acylation

3.1 Overview
-Lactam antibiotics have long been considered a cornerstone of therapy for many lifethreatening bacterial infections. Unfortunately, the production of -lactam degrading enzymes
known as -lactamases threatens their clinical use. A recent breakthrough in antibacterial drug
discovery was the broad-spectrum BLI known as avibactam. Avibactam is a unique BLI because
even though it can rapidly acylate a wide range of -lactamases, the covalent bond that it forms
with the catalytic serine residue is particularly stable to hydrolysis. Previous crystallographic
studies with class A -lactamases reveal that the catalytic water and Glu166, the general base for
deacylation, appear to be intact in the complex and capable of attacking the covalent linkage with
the inhibitor. Here I present a 0.83 Å resolution crystal structure of the class A -lactamase,
CTX-M-14, bound to avibactam, showing a unique active site protonation state trapped by the
inhibitor including a neutral Glu166 and a neutral Lys73. This structure suggests that the unique
side chain of avibactam (i.e., hydroxylamine-O-sulfonate) stabilizes a neutral Lys73, preventing
it from extracting a proton from Glu166. Subsequently, Glu166 is not able to serve as the general
base to activate the catalytic water for the hydrolysis reaction. My structure illustrates how
inhibitor binding can change the protonation states of catalytic residues.
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3.2 Introduction
-Lactamase production is the most common mechanism that Gram-negative bacteria use
to destroy -lactam antibiotics before they reach their targets, the PBPs, which are responsible
for cell wall synthesis [1]. -Lactamases are divided into two groups according to the mechanism
that they use to catalyze -lactam hydrolysis. Serine enzymes use an active site serine residue in
the covalent catalysis of the -lactam hydrolysis, whereas metalloenzymes use zinc ions for
catalysis. There are three classes of serine enzymes (A, C, and D), while there is only one class
of metalloenzymes, class B [2].
Class A -lactamases are the most prevalent class of -lactamase in hospital acquired
infections and are usually found in a variety of Gram-negative bacteria such as members of the
Enterobacteriaceae family [3, 4]. Class A -lactamases most commonly provide resistance to
penicillins and first/second-generation cephalosporins. Fortunately, bacteria producing these
enzymes generally remain susceptible to third-generation cephalosporins and carbapenems;
however, this situation is quickly changing with the emergence of class A -lactamases
displaying hydrolytic activity against third-generation cephalosporins and carbapenems [5, 6].
ESBLs can catalyze the hydrolysis of penicillins and first/second/third-generation
cephalosporins. Currently, the class A CTX-M -lactamases are the most commonly identified
ESBLs worldwide, with CTX-M-15 being the most frequent variant [2, 7]. Carbapenemases have
an even broader spectrum of activity than ESBLs, and can hydrolyze virtually all -lactam
antibiotics. The KPC class A -lactamase is the most common mechanism of carbapenem
resistance in the United States. Of the many KPC variants, KPC-2 is the most frequently
identified and characterized variant [2, 8, 9].
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The emergence of -lactamases prompted the search for novel inhibitors that could
reverse bacterial resistance against -lactam antibiotics. The first clinically available BLIs
inhibitors were clavulanic acid, sulbactam, and tazobactam, which are potent inhibitors of class
A (including CTX-M) and C -lactamases [10]. These inhibitors all contain a -lactam core
structure, enabling them to bind to the active site of class A and C -lactamases and form a
highly stable intermediate that permanently inactivates the enzyme. Specifically, clavulanic acid,
sulbactam, and tazobactam are suicide inhibitors of serine -lactamases because they covalently
bond to the catalytic serine residue and abolish enzymatic activity. However, these inhibitors can
be hydrolyzed by the more versatile carbapenemases (e.g., KPC-2 and MBLs) and consequently
have no activity against these enzymes [10, 11].
Avibactam is a rationally designed BLI targeting serine -lactamases that includes
ESBLs (CTX-M-15) and serine carbapenemases (KPC-2) in its spectrum of activity. Avibactam
has some unique properties that differentiates it from clavulanic acid, sulbactam, and
tazobactam: (1) avibactam does not contain a -lactam ring, but instead possesses a DBO
structure that incorporates features of -lactams into its scaffold (Fig. 3.1); and (2) avibactam is a
covalent, reversible inhibitor of serine -lactamases, which is a radical departure from the
irreversible inhibition seen in the -lactam-based BLIs (Fig. 3.2) [10-12].
To understand the mechanism by which avibactam possesses broad-spectrum of activity
against class A serine -lactamases, a high-resolution X-ray crystal structure of avibactam bound
to the CTX-M-15 class A -lactamase was solved [12]. This structure revealed that the catalytic
serine (Ser70) of this enzyme carries out nucleophilic attack on the carbonyl of the fivemembered cyclic urea, resulting in opening of the avibactam ring and acylation of the enzyme
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(Fig. 3.2) [12]. Acylation of CTX-M-15 can proceed through one of two pathways. The first
pathway involves Glu166 activating Ser70 for nucleophilic attack via a water molecule. The
second pathway proposes that Lys73 serves as the general base responsible for Ser70 activation.
Mutagenesis of Glu166 to a Gln demonstrated a comparable avibactam acylation rate to WT,
whereas mutating Lys73 to an Ala almost completely abolished avibactam acylation [13]. These
data suggest that Lys73 is the general base during acylation and plays a direct role in activating
Ser70 during avibactam acylation; however, there is still not a clear consensus as to which
pathway predominates [13].
Ser130 is a residue that plays a critical role in avibactam acylation and subsequently
deacylation. During acylation, Ser130 behaves as a general acid and donates a proton to the N6
nitrogen of avibactam following ring opening [14]. The reversible nature of avibactam inhibition
derives from its ability for recyclization (i.e., ring closure) after acylation (Fig. 3.2) [13, 15]. In
order for avibactam recyclization to occur, the N6 nitrogen must be deprotonated. During
deacylation, Ser130 now behaves as a general base, extracting a proton from the N6 nitrogen,
which facilitates ring closure [13]. The intact avibactam molecule can then go on an acylate other
-lactamases, or even the same -lactamase [15].
The complex that avibactam forms with serine -lactamases is very stable to hydrolysis.
In fact, recyclization of avibactam is favored over hydrolysis [16, 17]. Key questions remain as
to why the covalent bond avibactam forms with serine -lactamases is so stable against
hydrolysis, despite the presences of a water molecule perfectly positioned to attack the bond [12,
13]. Performing ultrahigh resolution X-ray crystallography on the CTX-M-14 class A lactamase, I attempt to answer this question by directly observing the protonation states of
Lys73, Ser130, and Glu166, residues implicated in a proton transfer process.
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3.3 Results and Discussion
3.3.1 Crystal structure of avibactam bound to CTX-M-14
The crystal structure of avibactam bound to CTX-M-14 was solved to 0.83 Å resolution.
In the active site, electron density corresponding to avibactam was identified (Fig. 3.3). The
electron density shows that there is a covalent linkage between avibactam and the catalytic
Ser70. Besides the acyl–enzyme covalent bond, there are four other key interactions observed
between the inhibitor and enzyme, which are the highly polar sulfate moiety, carboxamide group,
C7 carbonyl group, and piperidine ring (Fig. 3.4). The sulfate moiety binds in a polar region of
CTX-M-14, that commonly recognizes the carboxylate group on -lactam substrates [18-20].
The sulfate group has two conformations, with the dominant conformation establishing HBs with
Thr235 and Ser237, and interacts via attractive charges with Lys234 and Arg276. The
carboxamide group forms HBs with the sidechains of Asn104 and Asn132. The C7 carbonyl
group of avibactam is positioned within the oxyanion hole formed by the backbone amides of
Ser70 and Ser237. The piperidine ring forms a modest Van der Waals interaction with Tyr105.
In addition to these interactions, Ser130 is within HB distance (2.90 Å) of the N6 nitrogen,
which is hypothesized to play a role in the acylation and recyclization of avibactam as a general
acid/base [14].

3.3.2 Ultrahigh resolution reveals the protonation states of Lys73 and Glu166
The 0.83 Å resolution crystal structure of CTX-M-14/avibactam enabled direct
observations of the protonation state of two key catalytic residues, Lys73 and Glu166 (Fig. 3.5).
The unbiased Fo-Fc map shows that side chain amine nitrogen (N) of Lys73 has two protons,
indicating that it is neutral. The conformation of Lys73 is positioned to form a strong HB (2.8 Å)
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with Ser130 HG, where the proton on the Ser130 side chain is clearly visible in the Fo-Fc
electron density map. This observation is consistent with molecular dynamic (MD) simulations
studying avibactam recyclization during which dynamic stabilities of the HB between Ser130
and Lys73 were investigated [16]. These simulations showed that for 99% of the time, a HB is
present between Lys73 N and Ser130 HG, with some snapshots showing an N ··· H distance as
short as 1.5 Å, suggesting that a proton transfer from Ser130 to Lys73 is possible [16]. This
proton transfer would coincide with Ser130 behaving as a general base to extract a proton from
the N6 nitrogen, thereby promoting recyclization of avibactam.
From the crystal structure, it appears that the protonation state of Glu166 is closely tied
with that of Lys73. Analyzing the Fo-Fc map showed a protonated and neutral Glu166. In order
for the catalytic water to become activated for nucleophilic attack on the covalent linkage,
Glu166 must be able to transfer its proton to Lys73, to then act as a general base. However, this
process is energetically unfavorable based on MD simulations [21]. Instead, the Lys73-Ser130
dyad can serve as a better general base to activate the N6 nitrogen of avibactam for
intramolecular nucleophilic attack on the carbamyl linkage to reform the N6-C7 bond, and
generate the intact avibactam molecule (Fig. 3.2) [13, 16]

3.4 Conclusions
Together with previous high-resolution crystal structures of avibactam with class A lactamases, this new data allows us to track the transfer of a proton throughout the entire
acylation process, and demonstrate the essential role of Lys73 in transferring the proton from
Ser70 to Ser130 and ultimately to the N6 nitrogen of avibactam. Also revealed was that a
protonated Glu166 is unable to transfer a proton to Lys73, and subsequently cannot act as the
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general base to catalyze hydrolysis of the EI complex. In conjunction with computational
analysis, this structure also sheds new light on the stability and reversibility of the avibactam
acyl–enzyme complex, highlighting the effect of substrate functional groups in influencing the
protonation states of catalytic residues and subsequently the progression of the reaction.

3.5 Materials and Methods

3.5.1 Expression and purification of CTX-M-14
The CTX-M-14 gene was cloned into a modified plasmid vector pET-9a. E.coli BL21
(DE3) transformed with the plasmid pET-blaCTX-M-14 was cultured in LB broth containing
kanamycin at 100 μg/mL at 37 °C for 5 h. Overexpression of the CTX-M-encoding gene was
induced with 0.5 mM IPTG overnight at 20 °C. Cells were harvested by centrifugation (10,000 g
for 10 min at 4 °C) and then disrupted by ultrasonic treatment (four times for 30 sec, each time at
20 W). The extract was clarified by centrifugation at 48,000 g for 60 min at 4 °C. After addition
of 2 μg of DNase I (Roche), the supernatant was dialyzed overnight against 20 mM MES–NaOH
(pH 6.0). The purification was carried out by ion-exchange chromatography on a fast-flow CM
column (Amersham Pharmacia Biotech) in 20 mM MES buffer (pH 6.0) and eluted with a linear
0–0.15 M NaCl gradient. The enzyme was more than 95% homogeneous as judged by
Coomassie blue staining after SDS-PAGE. The purified protein was dialyzed against 5 mM Tris–
HCl buffer (pH 7.0) and concentrated to 20 mg/mL for crystallization.

69

3.5.2 Crystallization and structure determination
CTX-M-14 was crystallized in 1.0 M potassium phosphate buffer (pH 8.3) from hanging
drops at 20 °C. The final concentration of the protein in the drop ranged from 6.5 to 10 mg/mL.
Avibactam complex crystals were obtained through soaking methods, with a compound
concentration of 5.0 mM and soaking times varying from 3 h to 24 h. Crystals were cryoprotected in 1.0 M potassium phosphate buffer (pH 8.3) and 30% sucrose (w/v) and flash frozen
in liquid nitrogen. Diffraction was measured at 23-ID-B of GM/CA@APS at Advanced Photon
Source (APS), Argonne, Illinois. Diffraction data were indexed, integrated, and scaled with
HKL2000 [22]. The complex structure was refined with phenix.refine [23] from the PHENIX
suite. Model rebuilding was performed using WinCoot [24]. Figures were prepared using
PyMOL 1.3 (Schrödinger) [25] and Discovery Studio Visualizer [26].

3.6 Note to Reader #1
Figure 3.2 in this chapter was previously published by [12] Lahiri, S. D., Mangani, S.,
Durand-Reville, T., Benvenuti, M., De Luca, F., Sanyal, G., & Docquier, J. (2013). Structural
insight into potent broad-spectrum inhibition with reversible recyclization mechanism:
Avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC -lactamases.
Antimicrobial Agents and Chemotherapy, 57(6), 2496-2505. doi:10.1128/aac.02247-12 and has
been reproduced with permission (See Appendix 1).
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Figure 3.1. Chemical structure and numbering of atoms of avibactam.
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Figure 3.2. General mechanism of avibactam inhibition against serine -lactamases.
Adapted with permissions from [12]. See Appendix 1.
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Figure 3.3. Crystal structure of avibactam bound to CTX-M-14. The Fo-Fc omit electron
density map around avibactam is represented in blue and contoured at 2 .
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Figure 3.4. Schematic diagram of CTX-M-14/avibactam interactions. Various interactions
that avibactam forms with CTX-M-14 and avibactam are displayed in a schematic diagram
generated by Discovery Studio Visualizer.

74

N170
S130

Wat1

S70

E166

K73

Figure 3.5. Protonation states of active site residues in CTX-M-14/avibactam complex. The
2Fo-Fc electron density map is represented in blue and contoured at 3 . The Fo-Fc electron
density map is represented in red and contoured at 2 . Red sphere represents a water molecule.
Hydrogen atoms can be observed on K73, S130, and E166, indicating a neutral K73 and E166.

75

3.7 References
1. Sandanayaka, V., & Prashad, A. (2002). Resistance to -lactam antibiotics: Structure and
mechanism based design of -lactamase inhibitors. Current Medicinal Chemistry, 9(12),
1145-1165. doi:10.2174/0929867023370031
2. Bush, K., & Jacoby, G. A. (2009). Updated functional classification of -lactamases.
Antimicrobial Agents and Chemotherapy, 54(3), 969-976. doi:10.1128/aac.01009-09
3. Avci, F. G., Altinisik, F. E., Vardar Ulu, D., Ozkirimli Olmez, E., & Sariyar Akbulut, B.
(2016). An evolutionarily conserved allosteric site modulates beta-lactamase activity.
Journal of Enzyme Inhibition and Medicinal Chemistry, 31(sup3), 33-40.
doi:10.1080/14756366.2016.1201813
4. Fisher, J. F., Meroueh, S. O., & Mobashery, S. (2005). Bacterial resistance to -lactam
antibiotics: Compelling opportunism, compelling opportunity. ChemInform, 36(24).
doi:10.1002/chin.200524267
5. Rawat, D., & Nair, D. (2010). Extended-spectrum -lactamases in Gram negative
bacteria. Journal of Global Infectious Diseases, 2(3), 263. doi:10.4103/0974-777x.68531
6. Queenan, A. M., & Bush, K. (2007). Carbapenemases: The versatile -lactamases.
Clinical Microbiology Reviews, 20(3), 440-458. doi:10.1128/cmr.00001-07
7. Poirel, L., Nordmann, P., Ducroz, S., Boulouis, H., Arne, P., & Millemann, Y. (2013).
Extended-spectrum -lactamase CTX-M-15-producing Klebsiella pneumoniae of
sequence type ST274 in companion animals. Antimicrobial Agents and Chemotherapy,
57(5), 2372-2375. doi:10.1128/aac.02622-12
8. Mehta, S. C., Rice, K., & Palzkill, T. (2015). Natural variants of the KPC-2
carbapenemase have evolved increased catalytic efficiency for ceftazidime hydrolysis at
the cost of enzyme stability. PLOS Pathogens, 11(6), e1004949.
doi:10.1371/journal.ppat.1004949
9. Papp-Wallace, K. M., Winkler, M. L., Taracila, M. A., & Bonomo, R. A. (2015).
Variants of -lactamase KPC-2 that are resistant to inhibition by avibactam.
Antimicrobial Agents and Chemotherapy, 59(7), 3710-3717. doi:10.1128/aac.04406-14
10. Bush, K., & Bradford, P. A. (2016). -Lactams and -lactamase inhibitors: An overview.
Cold Spring Harbor Perspectives in Medicine, 6(8), a025247.
doi:10.1101/cshperspect.a025247
11. Drawz, S. M., & Bonomo, R. A. (2010). Three decades of -lactamase inhibitors.
Clinical Microbiology Reviews, 23(1), 160-201. doi:10.1128/cmr.00037-09
12. Lahiri, S. D., Mangani, S., Durand-Reville, T., Benvenuti, M., De Luca, F., Sanyal, G., &
Docquier, J. (2013). Structural insight into potent broad-spectrum inhibition with
reversible recyclization mechanism: Avibactam in complex with CTX-M-15 and
Pseudomonas aeruginosa AmpC -lactamases. Antimicrobial Agents and Chemotherapy,
57(6), 2496-2505. doi:10.1128/aac.02247-12
13. King, D. T., King, A. M., Lal, S. M., Wright, G. D., & Strynadka, N. C. (2015).
Molecular mechanism of avibactam-mediated -lactamase inhibition. ACS Infectious
Diseases, 1(4), 175-184. doi:10.1021/acsinfecdis.5b00007
76

14. Winkler, M. L., Papp-Wallace, K. M., Taracila, M. A., & Bonomo, R. A. (2015).
Avibactam and inhibitor-resistant SHV -lactamases. Antimicrobial Agents and
Chemotherapy, 59(7), 3700-3709. doi:10.1128/aac.04405-14
15. Krishnan, N. P., Nguyen, N. Q., Papp-Wallace, K. M., Bonomo, R. A., & Van den Akker,
F. (2015). Inhibition of Klebsiella -lactamases (SHV-1 and KPC-2) by avibactam: A
structural study. PLOS ONE, 10(9), e0136813. doi:10.1371/journal.pone.0136813
16. Choi, H., Paton, R. S., Park, H., & Schofield, C. J. (2016). Investigations on recyclisation
and hydrolysis in avibactam mediated serine -lactamase inhibition. Org. Biomol. Chem,
14(17), 4116-4128. doi:10.1039/c6ob00353b
17. Lahiri, S. D., Johnstone, M. R., Ross, P. L., McLaughlin, R. E., Olivier, N. B., & Alm, R.
A. (2014). Avibactam and class C -lactamases: Mechanism of inhibition, conservation
of the binding pocket, and implications for resistance. Antimicrobial Agents and
Chemotherapy, 58(10), 5704-5713. doi:10.1128/aac.03057-14
18. Leyssene, D., Delmas, J., Robin, F., Cougnoux, A., Gibold, L., & Bonnet, R. (2011).
Noncovalent complexes of an inactive mutant of CTX-M-9 with the substrate piperacillin
and the corresponding product. Antimicrobial Agents and Chemotherapy, 55(12), 56605665. doi:10.1128/aac.00245-11
19. Pemberton, O. A., Zhang, X., & Chen, Y. (2017). Molecular basis of substrate
recognition and product release by the Klebsiella pneumoniae carbapenemase (KPC-2).
Journal of Medicinal Chemistry, 60(8), 3525-3530. doi:10.1021/acs.jmedchem.7b00158
20. Tondi, D., Venturelli, A., Bonnet, R., Pozzi, C., Shoichet, B. K., & Costi, M. P. (2014).
Targeting class A and C serine -lactamases with a broad-spectrum boronic acid
derivative. Journal of Medicinal Chemistry, 57(12), 5449-5458. doi:10.1021/jm5006572
21. Sgrignani, J., Grazioso, G., De Amici, M., & Colombo, G. (2014). Inactivation of TEM-1
by avibactam (NXL-104): Insights from quantum mechanics/molecular mechanics
metadynamics simulations. Biochemistry, 53(31), 5174-5185. doi:10.1021/bi500589x
22. Otwinowski, Z., & Minor, W. (1997). Processing of X-ray diffraction data collected in
oscillation mode. Methods in Enzymology, 307-326. doi:10.1016/s0076-6879(97)76066x
23. Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W.,
Mustyakimov, M., Adams, P. D. (2012). Towards automated crystallographic structure
refinement with phenix.refine. Acta Crystallographica Section D: Biological
Crystallography, 68(4), 352–367. doi:10.1107/S0907444912001308
24. Emsley, P., & Cowtan, K. (2004). Coot: Model-building tools for molecular graphics.
Acta Crystallographica Section D Biological Crystallography, 60(12), 2126-2132.
doi:10.1107/s0907444904019158
25. DeLano W.L. (2002). The PyMOL user’s manual. DeLano Scientific, San Carlos, CA. pp
452.
26. Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2017,
San Diego: Dassault Systèmes, 2016.

77

Chapter 4:
The Influence of Binding Kinetics on Inhibition of KPC-2 by Vaborbactam in
Countering Bacterial Resistance

4.1 Overview
KPC-2 hydrolyzes nearly all -lactam antibiotics, including carbapenems, and is
responsible for antibiotic resistance in many pathogenic bacteria, particularly CRE. The recently
approved avibactam has been used as a KPC-2 inhibitor in the clinic, yet resistance has already
emerged. Here, I demonstrate that vaborbactam, a novel boronic-acid based BLI, behaves as a
slow, tight-binding inhibitor and can effectively reverse bacterial resistance caused by KPC-2,
including Ser130 mutants resistant to avibactam. In particular, vaborbactam displayed
significantly higher cell-based activity against KPC-2 than CTX-M-15, an ESBL, even though it
has similar binding affinities for both enzymes. Analysis of binding kinetics revealed a correlation
between vaborbactam's cell-based activity against KPC-2, and a slower koff value in comparison
to CTX-M-15. The molecular basis of this difference, as well as the roles of Ser130 in the
inhibition mechanisms of vaborbactam versus avibactam, is illustrated by the first crystal complex
structure of KPC-2 with vaborbactam, determined at 1.25 Å. My studies provide valuable insights
into the use of vaborbactam in combating antibiotic resistance, and the importance of binding
kinetics in novel antibiotic development.
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4.2 Introduction
CRE are an emerging health threat due to their production of carbapenemases, which are a
unique group of -lactamases that possess the ability to hydrolyze nearly all -lactam antibiotics
[1]. CRE infections are associated with high rates of morbidity and mortality worldwide due to
limited treatment options [2, 3]. One of the most common mechanisms of carbapenem resistance
among CRE is the production of the KPC-2 class A -lactamase [4]. Class A -lactamases, like
KPC-2, use a catalytic serine residue to mediate the opening of the -lactam ring, similar to class
C and D -lactamases [5]. In contrast, the last remaining class B -lactamases rely on zinc ions
for activity [6].
To address the growing problem of antibiotic resistance, numerous BLIs have been
developed that when combined with a -lactam, are therapeutic in the treatment of multi-drug
resistant bacterial infections [7]. However, some clinically available BLIs, such as clavulanic acid
and tazobactam (Fig. 4.1), have poor activity against KPC-2 [8, 9]. In 2015, a potent non--lactam
based BLI, known as avibactam (Fig. 4.1), was approved in combination with the third-generation
cephalosporin, ceftazidime, to combat bacteria producing KPC-2, AmpC, and ESBLs [10-12].
Unfortunately, clinicians have observed cases of avibactam resistance due to porin mutations and
plasmid-borne blaKPC-3 mutations [13-15]. These observations suggest that additional BLI
discovery is vital against this rapidly changing resistance determinant.
Antibiotic development requires both the discovery of novel lead chemical scaffolds and a
deep understanding of how these small molecules interact with their bacterial targets. Boronic
acids have undergone extensive investigation as broad-spectrum serine BLIs due to formation of
a stable covalent bond with the active site serine residue and the ability to readily diffuse through
the outer membrane of Gram-negative bacteria, facilitating their uptake [16]. A boronic acid
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transition state inhibitor (BATSI), known as S02030 (Fig. 4.1), was strategically designed to target
a wide variety of serine -lactamases, including ADC-7, KPC-2, and SHV-1 with nanomolar
potency [17]. Most recently, a cyclic boronic acid known as vaborbactam, has been shown to
possess potent inhibitory activity against many class A and C -lactamases [18]. Particularly,
vaborbactam can inhibit CTX-M, SHV, and CMY enzymes. Examining vaborbactam’s in vitro
activity revealed that it can potentiate meropenem (a carbapenem) against clinical isolates of E.
coli, Enterobacter cloacae, and K. pneumoniae expressing a wide range of serine -lactamases
from classes A and C [19].
I have extended my studies of vaborbactam to the clinically important KPC-2. In particular,
I am interested in how binding kinetics may influence the activity of vaborbactam. The importance
of binding kinetics in drug efficacy has received increasing attention with numerous studies
demonstrating that the residence time, i.e., the duration that the drug occupies the target binding
site, is a superior indicator of a drug’s in vivo efficacy versus the inhibitor constant Ki [20, 21].
However, most of these studies focused on how the residence time can influence the
pharmacokinetics of the drug inside animals or humans [22, 23]. It is largely unknown how binding
kinetics can impact the activity of a drug on the cellular level, especially relative to their
bactericidal effects. To characterize vaborbactam inhibition of KPC-2, I have performed binding
kinetic experiments, MIC assays, mutagenesis studies, and solved the first crystal structure of
vaborbactam bound to KPC-2. These results provide new insights into the unique properties of
vaborbactam in combating carbapenem resistance caused by KPC-2, as well as the influence of
binding kinetics on the cell-based activities of antibacterial compounds.
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4.3 Results and Discussion

4.3.1 Vaborbactam binding kinetics
Previously published crystal structures of vaborbactam with CTX-M-15 and AmpC lactamases revealed the formation of a covalent bond between the catalytic serine residue of the
enzyme and the boron atom of vaborbactam [18]. In agreement with these findings, a LineweaverBurk plot of KPC-2 inhibition by vaborbactam demonstrated that it behaves as competitive
inhibitor of this enzyme (Fig. S4.1).
The number of BLI molecules that are needed to inactivate one molecule of a -lactamase,
i.e., the stoichiometry or partition ratio, was also investigated. KPC-2 inhibition experiments using
varying BLI concentrations revealed that one mole of vaborbactam was required to inhibit one
mole of KPC-2 (Table 4.1). Avibactam demonstrated the same stoichiometry, while tazobactam
and clavulanic acid required a much higher ratio for complete enzyme inhibition as KPC-2 can
efficiently hydrolyze these suicide inhibitors [7]. Slow cleavage of avibactam by KPC-2 was
reported previously [24], thus prompting me to investigate the stability of vaborbactam to this
enzyme. Incubation of vaborbactam with KPC-2 for 18 h, with subsequent chromatographic
analysis, revealed no change in the amount of vaborbactam (data not shown), indicating no effect
of the enzyme on the vaborbactam chemical structure.
When studied using a reporter substrate technique, typical “fast on – fast off”, or reversible,
boronic BLIs (e.g., m-tolylboronic acid and 2-formylphenylboronic acid [25]) demonstrate a linear
KPC-2 inactivation profile, indicating that equilibrium between the enzyme and inhibitor is
quickly established (Fig. S4.2). My initial studies revealed a time-dependent decrease of Ki values
when the incubation time of vaborbactam and KPC-2 was increased from the standard 10 min up
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to 18 h (Fig. S4.3). That led me to hypothesize that, unlike other boronic BLIs, vaborbactam may
exhibit progressive inactivation profiles typical for covalent, irreversible inhibitors [26]. Indeed,
vaborbactam kinetic behavior was very similar to that demonstrated by tazobactam, with a slower
onset of inhibition and non-linear inhibition curves indicating progressive KPC-2 inactivation (Fig.
S4.4). This result suggests that vaborbactam’s interaction with KPC-2 follows a two-step kinetic
mechanism with initial formation of a non-covalent EI complex, characterized by the binding
constant K, which subsequently proceeds to a covalent interaction between the catalytic Ser70 of
KPC-2 and boron atom of vaborbactam in the EI complex. The last step is characterized by the
first-order rate constant k2. Independent determination of these values was impossible due to a
linear relationship between kobs and vaborbactam concentration values up to the highest inhibitor
concentration tested (data not shown). Similar kinetic behavior was previously reported for BLIs
from various structural classes [27]. Therefore, the second-order rate constant k2/K for the onset
of inhibition was determined. Vaborbactam and avibactam demonstrated comparable k2/K values
of 7.3 x 103 and 1.3 x 104 M-1*s-1, respectively (Table 4.2). The recovery of KPC-2 activity after
complete inhibition by vaborbactam was investigated by the jump dilution method [28]. This study
demonstrated that vaborbactam inhibition of KPC-2 can be reversed (Fig. S4.5). However, the
KPC-2 recovery rate was extremely slow with a koff of 0.000017 s-1, indicating an enzyme
residence time of 992 min (Table 4.2). For comparison, avibactam showed an approximately 10fold higher rate of activity recovery (koff = 0.00022 s-1). Knowing the rate for the onset of inhibition
and the koff rate allowed for calculation of the affinity, Kd, of the covalent complex (Table 4.2).
The two inhibitors have similar inactivation efficiency against KPC-2, but at least a 10-fold
difference in off-rates. As a consequence, vaborbactam appears to have a higher affinity for the
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covalent complex than avibactam. Overall, vaborbactam functions as a slow, tight-binding
inhibitor of KPC-2.
Analyzing the inhibition of vaborbactam among -lactamases revealed some key
differences in binding kinetics (Table 4.2). KPC-2 has a much slower koff (0.000017 s-1), as
compared to the ESBL, CTX-M-15 (0.00088 s-1). Ultimately, this leads to a much longer residence
for KPC-2 (992 min) versus CTX-M-15 (19 min).

4.3.2 Vaborbactam potentiation of aztreonam in KPC-2 and CTX-M-15 producing
E. coli
As previously shown, vaborbactam has widely varying binding kinetics against KPC-2 and
CTX-M-15 in terms of k2/K, koff, residence time, and Kd (Table 4.2). To observe how this would
translate to in vitro activity, we performed MIC experiments with aztreonam (a monobactam) and
varying concentrations of vaborbactam on KPC-2 and CTX-M-15 producing E. coli (Table 4.3).
Interestingly, only 0.15 g/mL of vaborbactam was needed to reduce the MIC of aztreonam 64fold, whereas 10 g/mL of vaborbactam was needed to reduce the MIC of aztreonam 64-fold.

4.3.3 Impact of S130G mutation on vaborbactam inhibition
Ser130 plays an important role in the catalytic mechanism of class A -lactamases,
including KPC-2 [7], and mutations at this position significantly affect interactions with substrates
and inhibitors, including the recently approved avibactam [24, 29]. The effect of the S130G
substitution on vaborbactam potentiation of various antibiotics was studied in microbiological
experiments with a strain of P. aeruginosa, PAM1154 [30] that lacks efflux pumps and carries
plasmids expressing the WT and the mutant blaKPC-2. Consistent with earlier studies, KPC-2
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S130G lost the ability to hydrolyze the majority of -lactam antibiotics [24, 29, 31]. P. aeruginosa
producing the KPC-2 S130G variant demonstrated resistance to the penicillins, carbenicillin, and
piperacillin, but not to other -lactams (Table S4.1). Subsequently, carbenicillin and piperacillin
were chosen to study the concentration response to vaborbactam using a checkerboard
methodology (Table 4.4). As previously reported, cells producing KPC-2 S130G were highly
resistant to avibactam potentiation of penicillins [29, 31]; carbenicillin and piperacillin MICs
against the KPC-2 WT producing strain were reduced 512- to 1024-fold by avibactam at 32 g/mL,
and only 4- to 8-fold against the strain that produced KPC-2 S130G. Notably, the S130G
substitution did not affect antibiotic potentiation by vaborbactam.
Studies with purified enzymes confirmed that the Ki value for avibactam inhibition of
KPC-2 S130G was almost 6,000-fold higher than that for the WT KPC-2: 70 M vs 0.012 M. At
the same time, the Ki of vaborbactam decreased from 0.034 M for the WT KPC-2 to 0.011 M
for the S130G mutant. Detailed kinetic studies confirmed the significant effect of the S130G
substitution on acylation efficiency of avibactam [24, 31, 32]; it was decreased almost 1,000-fold
(Table 4.2). Conversely, vaborbactam inactivated the KPC-S130G variant with an almost 10-fold
higher efficiency compared to its inactivation of the WT KPC-2. Another unexpected impact of
S130G on vaborbactam kinetics was an over 200-fold increase in the rate of recovery of enzymatic
activity (Table 4.2). Of note, due to an increase in the rate of onset of inhibition (k2/K), the Kd
value remained in the nanomolar range, providing a possible explanation as to why the S130G
mutation did not impact the antibiotic potentiation activity of vaborbactam.
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4.3.4 Structure determination of vaborbactam with KPC-2
To understand how vaborbactam achieves potent inhibition of KPC-2 requires structural
information to supplement our previously obtained structures of vaborbactam bound to CTX-M15 and AmpC [18]. Therefore, I co-crystallized KPC-2 with vaborbactam and solved the complex
structure to 1.25 Å (Fig. 4.2, Table S4.2). KPC-2/vaborbactam co-crystals belong to the space
group P22121, with one molecule in the asymmetric unit. The Fo-Fc map showed an unambiguous
density in the KPC-2 active site corresponding to two closely related conformations of
vaborbactam, differing from one another by a flip of the thiophene ring (Fig. 4.2A). Vaborbactam
forms several HBs and extensive hydrophobic interactions with the enzyme (Fig. 4.2A). The NH
of the amide group of vaborbactam donates a HB to the Thr237 backbone carbonyl, while the
carbonyl of the same amide group of vaborbactam accepts a HB from the Asn132 sidechain amide
NH2. The carboxylate group of vaborbactam is extensively coordinated by the hydroxyl side chains
of Ser130, Thr235, and Thr237. The thiophene moiety of the inhibitor re-orients inward to make
hydrophobic interactions with Trp105. The interactions that vaborbactam makes with KPC-2
largely mimic the interactions that the -lactam antibiotics, cefotaxime and faropenem, form with
KPC-2 [33].
Like most serine hydrolases, the KPC-2 active site contains an “oxyanion hole”, which is
a small subpocket surrounded by several HB donor atoms that coordinate the carbonyl group
oxygen of the substrate next to the scissile bond [34, 35]. In KPC-2, it is formed by the backbone
amide NH groups of residues Ser70 and Thr237. A distinct feature of the vaborbactam complex is
the mode of interaction with the oxyanion hole. Typically, substrates and inhibitors engage it with
a single acceptor (oxygen atom or hydroxyl) [36-40]; vaborbactam on the other hand, inserts two
oxygen atoms (exocyclic and endocyclic) into the oxyanion hole so that the Ser70 NH group is
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interacting mostly with the exocyclic oxygen and the Thr237 NH group is interacting with
endocyclic oxygen (Fig. 4.2A).
Vaborbactam induces some conformational changes in the KPC-2 active site upon binding
(Fig. 4.2B). In the apoenzyme (PDB ID code: 5UL8 [33]), Trp105 alternates between two
conformations that flank opposite sides of the active site, whereas in the complex structure, Trp105
adopts two conformations that are positioned to make hydrophobic contacts with the sixmembered ring and thiophene moiety of vaborbactam. One conformation of Trp105 is similar to a
conformation observed in the apoenzyme, whereas the other conformation is unique to the
particular complex, allowing the protein to establish more non-polar contacts with vaborbactam.
In the apoenzyme, Ser130 also has two conformations. Conformation 1 forms a weak HB (3.5 Å)
with Lys73 and is the conformation normally observed in class A -lactamases, whereas
conformation 2 establishes a strong HB (2.7 Å) with Lys234 [33]. In the complex structure, Ser130
adopts a single conformation, conformation 2, forming a HB with the vaborbactam carboxylate
group.

4.4 Conclusions
Bacterial antibiotic resistance to -lactam antibiotics is a significant health threat
worldwide. Of notable health concern is the KPC-2 class A -lactamase due to its broad-substrate
profile that includes penicillins, extended-spectrum cephalosporins, and carbapenems. My
biochemical and structural analyses have provided important insights into the binding kinetics and
molecular interactions underlying the clinical utility of vaborbactam, a unique cyclic boron-based
BLI, in countering bacterial resistance caused by KPC-2 and its mutants.
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Like other boronic acid inhibitors, vaborbactam acts as a covalent, yet reversible, ligand
for -lactamases [41-43]. The apparent Ki values of these inhibitors are usually determined by
steady-state kinetics using the hydrolysis reaction with reporter substrates such as nitrocefin. Due
to the formation of a covalent bond, these inhibitors frequently have a slow koff, and the binding to
the protein may not reach equilibrium during the biochemical assay. This is especially true for
vaborbactam, whose residence time for KPC-2 is more than 10X longer than the duration of the
experiment, usually in the range of 10-20 min. As a result, this can lead to an underestimate of the
true Kd/Ki value. In my previous study using steady-state kinetics, vaborbactam displayed similar
activities against both KPC-2 and CTX-M-15 [18]. My latest results provide a more accurate
picture of the inhibition of these two enzymes by vaborbactam. The Kd value against KPC-2 is
approximately 5X lower than previously reported. In comparison, the Kd for CTX-M-15 is similar
to previous studies [18]. This is likely due to the shorter residence time of vaborbactam for CTXM-15, which allows the binding to reach equilibrium during the length of the assay.
The longer residence time of vaborbactam for KPC-2 (992 min), in comparison to CTXM-15 (19 min), has translated into a significantly improved cell-based activity against the former
enzyme than the latter. At 0.3 g/mL, vaborbactam decreased the MIC of aztreonam by >100-fold
against KPC-2 expressing E. coli, but only 2-fold for CTX-M-15. Recent studies have highlighted
the importance of residence time in the in vivo efficacy of many drugs, targeting both human and
bacterial proteins [20-23]. For antibacterial targets, it has been suggested that the residence time
should be at least comparable to the bacterial generation time (e.g., 20 min.) [7]. The residence
time of vaborbactam for both KPC-2 and CTX-M-15 satisfies this criterion. The significant
improvement in the cell-based activity suggests that a long residence time is important for the
potency of antibacterial compounds, at least in the case of BLIs, even without considering the
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pharmacokinetics inside the human body. At the same time, it raises the question as to why a
residence time longer than the bacterial generation time can still be beneficial for antibiotic utility.
For BLIs, this may be due to potential -lactamase activity even after bacterial cell death, as a
result of the diffusion of both -lactamases and antibiotics.
The high binding affinity and long residence time of vaborbactam for serine -lactamases
is mostly derived from the covalent bond between the catalytic serine and the boron atom.
However, the different binding kinetics of KPC-2 and CTX-M-15 illustrates the contribution of
non-covalent interactions to the activity of vaborbactam. Vaborbactam was previously solved in
the active site of CTX-M-15 to 1.50 Å resolution (PDB ID code: 4XUZ [18]). There are many
similarities between vaborbactam in KPC-2 and CTX-M-15 (Fig. 4.3). Both the endocyclic and
exocyclic oxygens of the vaborbactam ring enter and interact with the oxyanion hole formed by
the backbone NH groups of Ser70 and Thr237 (in the case of KPC-2) and Ser70 and Ser237 (in
the case of CTX-M-15). The exocyclic oxygen forms a HB with the NH group of Ser70, whereas
the endocyclic oxygen HBs with the NH group of Thr237 in KPC-2 or Ser237 in CTX-M-15.
Unlike CTX-M-15, KPC-2 and related carbapenemases possess a disulfide bond between
the adjacent Cys69 and Cys238, that has been demonstrated to be important for activity [44, 45].
The presence of this disulfide bond appears to have a structural impact on the architecture of the
KPC-2 active site as compared to the CTX-M-15 active site. The disulfide bond results in an
outward shift of Gly239 and Val240, which contributes to the re-orientation of the thiophene
moiety of vaborbactam due to potential steric clashing. Interestingly, the disulfide bond may also
pre-adjust the backbone conformation around the oxyanion hole to allow insertion of the
endocyclic and exocyclic oxygen atoms of vaborbactam. This difference is particularly evident
when comparing CTX-M-15 structures (apo, PDB ID code: 4HBT [46]; vaborbactam, PDB ID
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code: 4XUZ [18]; and avibactam, PDB ID code: 4HBU [46]). Indeed, vaborbactam binding to
CTX-M-15 is accompanied by ~ 0.6 Å “bulging” of the backbone at Ser237 (Fig. 4.4A), enlarging
the oxyanion hole (as compared to less than 0.2 Å movement for avibactam). On the other hand,
virtually no backbone movement is seen around the oxyanion hole in our KPC-2/vaborbactam
structure when compared with an apo structure of KPC-2 (PDB ID code: 5UL8 [33]); however,
the structure of avibactam bound to KPC-2 (PDB ID code: 4ZBE [24]) does result in backbone
shifts upstream, at Cys238 and especially Gly239 (Fig. 4.4B). This observation may in part explain
the potency of vaborbactam against class A carbapenemases.
One major difference between the KPC-2 and CTX-M-15 vaborbactam complexes is the
conformation of the thiophene moiety. In CTX-M-15, the thiophene moiety assumes a linear
conformation, whereas in KPC-2 the thiophene moiety bends inward to form hydrophobic
interactions with Trp105 (Fig. 4.3). The presence of the large, non-polar tryptophan residue at
position 105 in KPC-2 versus the smaller, and more polar tyrosine residue at position 105 in CTXM-15 likely contributes to this observation. In comparison to Trp105 in KPC-2, Tyr105 in CTXM-15 establishes fewer interactions with vaborbactam. This is due not only to the smaller size of
Tyr105, but also due to its relative rigidity, which prevents it from moving closer to the ligand,
like the second conformation of Trp105. In fact, this is a general trend observed in several CTXM and KPC-2 structures, which underscores the versatility of Trp105 in adapting to different
ligands and contributing to the broad-spectrum activity of KPC-2 [33, 40, 47-49].
Overall, the more extensive non-covalent interactions between vaborbactam and KPC-2
may explain its longer residence time compared with CTX-M-15; however, the increased
complementarity may have been achieved with a significant entropic cost on the protein and the
ligand, and led to the slower on-rate for KPC-2 (Table 4.2). On the protein side, the need for an
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optimal Trp105 conformation can affect the kon rate, albeit on a smaller scale. This is reminiscent
of previous studies showing protein conformational changes usually accompany long residence
times [21, 50]. On the ligand side, vaborbactam adopts a very compact conformation in KPC-2,
which affords little conformational freedom. In comparison, significant movement of the
thiophene arm can be accommodated in the extended conformation in the CTX-M-15 active site.
The strict conformational requirement for vaborbactam in the KPC-2 active site may be another
factor contributing to the slower on-rate than CTX-M-15.
Another interesting observation is that the S130G mutation seems to significantly increase
the on-rate for KPC-2. I have recently found that Ser130 mutations in CTX-M-14 significantly
increase the flexibility of the active site loop containing Ser130 (unpublished data). I hypothesize
that similar effects in KPC-2 may lead to a more open active site, which may reduce the
conformational restraints on vaborbactam.
Although avibactam has been successfully used to target carbapenem-resistance caused by
KPC-2, its clinical utility is threatened by emerging resistance mutations such as S130G [24, 31,
32]. The Ser130 sidechain plays a significant role in the catalytic mechanism of class A lactamases, donating a proton to the nitrogen atom upon cleavage of the amide (lactam) bond [29].
Indeed, S130G mutant enzymes generally have much lower catalytic efficiency, with the
remaining activity attributed to replacement of the Ser130 sidechain by a water molecule.
Accordingly, avibactam and other inhibitors that depend on an Ser130-mediated acylation
mechanism are strongly impacted by this mutation, resulting in substantial resistance [32]. Ser130
mutations may be particularly detrimental to avibactam activity because they also affect the
recyclization of the avibactam ring, which reverses the acylation reaction and allows the inhibitor
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to be recycled [51]. In comparison, the boronate moiety of vaborbactam is not interacting with
Ser130 and therefore, formation of the covalent adduct should not be affected by this residue.
In conclusion, vaborbactam achieves nanomolar potency against KPC-2 due to its covalent
and extensive non-covalent interactions with conserved active site residues. Its remarkable
residence time on KPC-2 correlates with its favorable pharmacological properties. Ultimately,
these in vitro findings corroborate the idea that a slow off-rate and long residence time translate to
potent cell-based activity. Vaborbactam has shown promising results when combined with the
carbapenem meropenem, and is marketed as Vabomere, which has been recently approved by the
FDA. Vabomere provides a promising strategy for the treatment of serious Gram-negative
infections caused by bacteria resistant to carbapenem antibiotics.

4.5 Materials and Methods

4.5.1 Generation of KPC-2 mutants
Mutations in the KPC-2 gene cloned in either pUCP24 or pET28a plasmids were
introduced using “QuikChange Lightning Site-Directed Mutagenesis Kit” (Agilent Technologies).
The presence of desired mutations and the lack of unwanted ones were confirmed by DNA
sequencing of the entire KPC-2 gene.

4.5.2 Determination of MIC values and vaborbactam potentiation experiments
For microbiological studies, KPC-2 WT and its mutant genes were cloned in pUCP24
shuttle vector. Resulting plasmids were transformed into P. aeruginosa PAM1154 strain. MIC
values for various antibiotics were determined by the standard broth microdilution method using
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cation adjusted Mueller-Hinton Broth [52]. Potentiation of antibiotic activity by vaborbactam in
bacterial strains carrying WT and mutants KPC-2 genes were performed using standard checker
board assay [53]. All microbiological studies were performed with 15 g/mL of gentamycin
present in the media.

4.5.3 Evaluation of KPC-2 mutant proteins expression level in PAM1154 strain
Bacterial cells carrying plasmids expressing KPC-2 mutants were grown in liquid media
till OD600=0.7-0.9 and diluted to final OD600=0.5. 500 L of cell culture were spun down and
resulting pellet was resuspended in 500 L of gel-loading buffer. 20 L of cell lysate was loaded
on 8-16% SDS-PAGE. After gel transfer membrane was probed with custom produced rat antiKPC-2 antibodies and subsequently treated with secondary goat anti-rat HRP-conjugated
antibodies. Anti-RNA polymerase -subunit monoclonal antibodies (Abcam, #ab12087) were
used as loading control.

4.5.4 Purification of KPC-2 WT and mutant proteins for biochemical studies
For protein expression, the full KPC-2 gene coding sequence with its Shine-Dalgarno box
was cloned into the pET28a vector that produced a construct with periplasmic KPC-2 secretion
and a 6xHis-tag on its C-terminus. The recombinant plasmids were transformed into E. coli
BL21(DE3) pLysS cells. 2 mL of overnight culture was inoculated in 1 L of LB media with 50
g/mL of kanamycin and 20 g/mL of chloramphenicol and grown at 37 oC with 300 RPM shaking
until reaching an OD600=0.7-0.8. IPTG was added to 0.2 mM concentration and cells continued to
grow for an additional 3 h. Cells were harvested by centrifugation and the cell pellet was
resuspended in 40 mL of ice-cold 50 mM Tris-HCl pH 8.0, 500 mM sucrose, 1 mM EDTA, and 1
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tablet of complete protease inhibitor tablet (Roche). Suspension was incubated on ice with six
cycles of 15 sec vortexing and 5 min pause between them. Suspension was centrifuged for 30 min
at 30,000 x g, supernatant was collected, sonicated for 30 sec to reduce viscosity and MgCl 2 and
imidazole were added to 2 mM and 5 mM concentrations, respectively. Lysate was loaded by
gravity flow onto a 1 mL column with HisPur Cobalt Resin (Thermo Scientific) pre-equilibrated
with 50 mM Na-phosphate pH 7.4, 300 mM NaCl, 5 mM imidazole buffer. Column was washed
with 40 mL of the same buffer and consequently 6xHis-tag protein was eluted with 50 mM Naphosphate pH 7.4, 300 mM NaCl, 70 mM imidazole buffer. All wash and elution fractions were
analyzed by 8-16% SDS-PAGE. Fractions containing target protein were pooled, concentrated,
and dialyzed against 50 mM Na-phosphate pH 7.0. Purity of all proteins were at least 95% as
determined by SDS-PAGE. Protein preparations were aliquoted and stored at -20 oC until further
use.

4.5.5 Determination of Km and kcat values for nitrocefin cleavage by KPC-2 and
mutant proteins
Purified protein was mixed with various concentrations of nitrocefin (NCF) in 50 mM Naphosphate pH 7.0, 0.1 mg/mL bovine serum albumin (BSA) (reaction buffer) and substrate
cleavage was monitored at 490 nm every 10 sec for 10 min on SpectraMax plate reader at 37 oC.
Initial rates of NCF cleavage were calculated and used to obtain Km and kcat values with Prism
software (GraphPad).
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4.5.6 Determination of Km and kcat Values for meropenem cleavage by KPC-2 and
mutant proteins
Purified protein was mixed with various concentrations of meropenem in reaction buffer
and substrate cleavage was monitored at 294 nm every 30 sec for 30 min on SpectraMax plate
reader at 37 oC. Initial rates of meropenem cleavage were calculated and used to obtain Km and
kcat values with Prism software (GraphPad).

4.5.7 Determination of vaborbactam Ki values for KPC-2 and mutant proteins using
NCF as substrate
Protein was mixed with various concentrations of inhibitors in reaction buffer and
incubated for 10 min at 37 oC. 50 M NCF was added and substrate cleavage profiles were
recorded at 490 nm every 10 sec for 10 min. Ki values were calculated by method of Waley, S.G
[54].

4.5.8 Determination of vaborbactam Ki values for KPC-2 and mutant proteins using
meropenem as substrate
Protein was mixed with various concentrations of inhibitor in reaction buffer and incubated
for 10 min at 37 oC. 100 M meropenem solution was added and substrate cleavage profiles were
recorded at 294 nm every 30 sec for 30 min. Ki values were calculated as described in [54].

4.5.9 Stoichiometry of KPC-2 and mutant proteins inhibition
Enzyme at 1 M in reaction buffer was mixed with BLI at molar ratios varying from 64 to
0.0625. After 30 min incubation at 37 oC, reaction mixture was diluted 200-fold and enzyme
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activity was measured with NCF as described above. Stoichiometry of inhibition was determined
as a minimal BLI:enzyme ratio reducing enzyme activity to at least 10%.

4.5.10 Determination of vaborbactam k2/K inactivation constant for WT KPC-2 and
mutant proteins
Inactivation kinetic parameters were determined by the reporter substrate method [55] for
slow, tight binding inhibitor kinetic scheme.
K

k2

E + I ↔ EI ↔ EI*
k-2
Protein was quickly mixed with 100 M nitrocefin and various concentrations of BLI in reaction
buffer and absorbance at 490 nm was measured immediately every two seconds for 180 sec on
SpectraMax plate reader (“Molecular Devices”) at 37 oC. Resulting progression curves of OD490
vs time at various BLI concentrations were imported into Prism software (“GraphPad”) and pseudo
first-order rate constants kobs were calculated using the following equation:

P=V0*(1-e-kobs*t)/kobs, where Vo - uninhibited KPC-2 rate. Kobs values calculated at various
vaborbactam concentrations were fitted in the following equation
kobs=k-2+k2/K*[I]/(1+[NCF]/Km(NCF)), where
k2/K - inactivation constant
[I] – inhibitor concentration
[NCF] – nitrocefin concentration
Km(NCF) - Michaelis constant of NCF for KPC-2
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4.5.11 Determination of Koff rates of enzyme activity recovery after KPC-2 and
mutants’ inhibition by vaborbactam
Purified enzyme at 1 M concentration in reaction buffer was mixed with BLIs at 8-fold
higher concentration than its stoichiometry ratio (determined in preliminary stoichiometry
experiments). After 30 min incubation at 37 oC, reaction mixture was diluted 30,000-fold in
reaction buffer and 100 L of diluted enzyme was mixed with 100 L of 400 M NCF in reaction
buffer. Absorbance at 490 nm was recorded every minute during 4 h at 37 oC. Resulting reaction
profiles were fitted into the following equation using Prism software (GraphPad) to obtain Koff
values: P=Vs*t+(Vo-Vs)*(1-e-koff*t)/koff, where
Vs – uninhibited enzyme velocity, measured in the reaction with enzyme and no inhibitor
Vo – completely inhibited enzyme velocity, measured in the reaction with no enzyme and NCF
only

4.5.12 Crystallization experiments
KPC-2 was expressed and purified as previously described [33]. Vaborbactam was dissolved in
DMSO as a 200 mM stock solution and stored at -20 oC. Prior to crystallization setup, 5 mM
vaborbactam was gently mixed with 11.6 mg/mL His-tag KPC-2 and incubated at room
temperature for 5 min. Crystal trays for His-tag KPC-2 were set with 500 L wells and crystal
drops consisted of 0.5 L protein and 1 L of crystallization solution (2 M ammonium sulfate and
5% (v/v) ethanol). Droplets (1.5 L) were microseeded with 0.5 L of diluted seed stock.
Crystallization trays were stored at 20 oC and crystals typically appeared within 5 days. Crystals
were cryo-protected in mother liquor supplemented with 20% (v/v) glycerol and flash frozen with
liquid nitrogen.
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4.5.13 Data collection and structure determination
Data for the KPC-2/vaborbactam structure was collected at the Advanced Photon Source (APS)
beamline 19-ID. Diffraction data was indexed and integrated with iMosflm [56] and scaled with
SCALA [57] from the CCP4 suite [58]. Phasing was performed using molecular replacement with
the program Phaser [59] with the KPC-2 structure (PDB ID code: 5UL8 [33]). Structure refinement
was performed using phenix.refine [60] in the Phenix suite [61] and model building in WinCoot
[62]. The program eLBOW [63] in the Phenix suite was used to obtain geometry restraint
information. The final model quality was assessed using MolProbity [64]. Figures were prepared
using PyMOL 1.3 (Schrödinger) [65].

4.6 Note to Reader #1
The binding kinetic experiments, MIC assays, and mutagenesis studies were contributed
by The Medicines Company, which are the developers of vaborbactam and Vabomere
(vaborbactam/meropenem).

4.7 Note to Reader #2
Supplementary figures (Fig. S4.1, S4.2, S4.3, S4.4, and S4.5) and tables (Table S4.1 and
S4.2) are located in Appendix 2.
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Figure 4.1. Chemical structures of clinically available and promising new BLIs.
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Figure 4.2. Vaborbactam bound to KPC-2 active site. (A) The unbiased Fo-Fc map (gray) of vaborbactam in the active site
of KPC-2 contoured at 3 . KPC-2 residues and the vaborbactam molecule are green. HB are depicted by dashed lines. (B)
Superimposition of KPC-2/vaborbactam (green) and KPC-2 apo (PDB ID code: 5UL8, purple).
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Figure 4.3. Superimposition of KPC-2/vaborbactam and CTX-M-15/vaborbactam structures. KPC2/vaborbactam (green) with CTX-M-15/vaborbactam (PDB ID code: 4XUZ, purple). Red arrow indicates a
backbone shift.

100

A

B

S237

T237
T235

T235
G240

G239
G238
S70

S70
C69

C238
C69

Figure 4.4. Vaborbactam induces a backbone conformational changes near the oxyanion hole. (A) CTX-M-15 apo
(PDB ID code: 4HBT, purple), avibactam (PDB ID code: 4HBU, blue), and vaborbactam (PDB ID code 4XUZ, green).
(B) KPC-2 apo (PDB ID code: 5UL8, purple), avibactam (PDB ID code: 4ZBE, blue), and vaborbactam (green).
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Table 4.1. Stoichiometry of KPC-2 inhibition by various BLIs

BLI

Stoichiometry of KPC-2 inhibition

Vaborbactam

1

Avibactam

1

Tazobactam

>64

Clavulanic acid

>64
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Table 4.2. Kinetic parameters of inhibition of KPC-2 and CTX-M-15 by vaborbactam and avibactam
-Lactamase

BLI

k2/K (M-1* s-1)

koff, s-1

Residence time, min

Kd, nM

KPC-2

Vaborbactam

7.3 X 103

0.000017

992

2.3

KPC-2 S130G

Vaborbactam

6.7 X 104

0.0044

3.8

66

KPC-2

Avibactam

1.3 x 104

0.00022

77

17

KPC-2 S130G

Avibactam

9.0

ND

ND

ND

CTX-M-15

Vaborbactam

2.3 x 104

0.00088

19

38
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Table 4.3. Concentration-response of aztreonam potentiation by vaborbactam against engineered E. coli
strains expressing KPC-2 and CTX-M-15
Aztreonam MIC (g/mL) in the presence of varied concentrations of vaborbactam (g/mL)
-Lactamase

0

0.15

0.3

0.6

1.25

2.5

5

10

MPC16

KPC-2

16

0.25

≤0.125

≤0.125

≤0.125

≤0.125

≤0.125

≤0.125

≤0.15

CTX-M-15

8

8

4

2

1

0.5

0.25

≤0.125

2.5
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Table 4.4. Concentration-response of carbenicillin and piperacillin potentiation by vaborbactam and avibactam
against KPC-2 and KPC-2 S130G producing strain of P. aeruginosa
Antibiotic MIC (g/mL) in the presence of various concentrations of BLIs (g/mL)
Plasmid

BLI

Antibiotic

0

1

2

4

8

16

32

KPC-2

Vaborbactam

Carbenicillin

1024

64

16

8

4

2

1

KPC-2 S130G

Vaborbactam

Carbenicillin

128

4

2

1

≤0.5

≤0.5

≤0.5

KPC

Avibactam

Carbenicillin

1024

64

64

32

16

8

2

KPC-2 S130G

Avibactam

Carbenicillin

128

128

128

64

64

64

32

KPC-2

Vaborbactam

Piperacillin

128

1

0.5

0.25

≤0.13

≤0.13

≤0.13

KPC-2 S130G

Vaborbactam

Piperacillin

128

2

0.5

0.25

0.25

≤0.13

≤0.13

KPC-2

Avibactam

Piperacillin

128

2

1

0.5

0.25

≤0.13

≤0.13

KPC-2 S130G

Avibactam

Piperacillin

128

128

64

64

64

32

16
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Chapter 5:
Leveraging Protein Promiscuity in Ligand Binding to Develop Broad-Spectrum
Carbapenemase Inhibitors
5.1 Overview
Gram-negative bacterial pathogens expressing the serine -lactamase KPC-2 and the
MBLs NDM-1 and VIM-2 threaten the clinical utility of all -lactam antibiotics. These enzymes
have a broad-substrate profile, most likely due to the hydrophobicity and flexibility of their active
sites, particularly for the metalloenzymes. Here I demonstrate that this promiscuity in ligand
recognition may expose a potential weakness that can be exploited through rational drug design.
Using a fragment-based approach, I report the identification of a series of phosphonate compounds
that represent the first cross-class, non-covalent inhibitors of KPC-2, NDM-1, and VIM-2.
Although my lead optimization specifically targeted KPC-2, the increase in KPC-2 inhibition was
mirrored by improvement in activity against NDM-1, and particularly VIM-2. These findings
provide novel chemical scaffolds for antibiotic development against bacteria co-producing serine
carbapenemases and MBLs, and suggest that protein promiscuity can be leveraged in developing
high affinity cross-class inhibitors.

5.2 Introduction
-Lactam antibiotics are among the oldest and most widely used drugs used to treat a
diverse range of bacterial infections [1]. The most common mechanism of -lactam antibiotic
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resistance involves the production of -lactamase enzymes that hydrolyze them [2]. There are four
classes of -lactamases (A, B, C, and D), which differ from one another based on their amino acid
sequence and mechanism of action. Class A, C, and D -lactamases are active-site serine enzymes,
whereas class B -lactamases require one or two zinc ions for activity [3, 4].
Carbapenems (e.g., imipenem, meropenem, doripenem, and ertapenem) are the most potent
-lactam antibiotics, and are often considered the “last-resort antibiotics” used to treat multi-drug
resistant infections [5-7]. Unfortunately, the recent emergence of CRE and multi-drug resistant P.
aeruginosa threatens the use of all -lactam antibiotics. CRE infections are associated with high
rates of morbidity and mortality worldwide due to limited treatment options [8]. The CDC
estimates that there are over 9,000 cases of CRE and 6,700 cases of multi-drug resistant P.
aeruginosa infections a year in the United States [9]. Carbapenem resistance in CRE and P.
aeruginosa is usually mediated by the production of carbapenem hydrolyzing enzymes known as
carbapenemases, and/or by the combination of porin loss and hyperproduction of AmpC or an
ESBL [10-12]. Most carbapenemases are broadly promiscuous enzymes that can catalyze the
hydrolysis of multiple -lactam substrates including not only carbapenems, but also penicillins,
cephalosporins, monobactams, and -lactam-based BLIs [7, 13]. These enzymes belong to either
class A and D -lactamases (serine carbapenemases) or molecular class B (MBLs) [14]. Of notable
health concern is the serine carbapenemase KPC-2 (class A), and the MBLs NDM-1 and VIM-2
(class B), all of which are commonly isolated from CRE, P. aeruginosa, and other Gram-negative
pathogens [13].
To address the growing problem of -lactam antibiotic resistance, numerous inhibitors
have been developed to target -lactamases. However, most of these inhibitors target serine 113

lactamases and none in clinical use are active against both serine -lactamases and MBLs [13]. In
general, the BLIs clavulanic acid, sulbactam, and tazobactam display potent activity against many
class A -lactamases, with only limited activity against class C and D -lactamases, and no activity
against KPC-2 and class B -lactamases [13, 15]. Recently, novel BLIs such as avibactam and
vaborbactam (Fig. 5.1) have been demonstrated to inhibit the class A, C, and D -lactamases,
including KPC-2, but possess no activity against MBLs [16-18]. Additionally, a naturally produced
polyamino acid called Aspergillomarasmine A (AMA) (Fig. 5.1) derived from the mold
Aspergillus versicolor has been observed to potently inhibit MBLs by acting as a chelating agent
[19, 20]. Unfortunately, there are some drawbacks to AMA, which include its non-specific
inhibition as demonstrated by its ability to chelate essential metal ions required by human
metalloproteins, and its inability to inhibit serine -lactamases [19, 21]. Therefore, there is a
serious unmet medical need for the development of novel compounds that can simultaneously
target serine carbapenemases and MBLs commonly encountered in multi-drug resistant bacterial
infections.
Developing a single cross-class inhibitor that can inactivate both serine carbapenemases
and MBLs has long been considered a challenging feat due to the structural and mechanistic
heterogeneity between these enzymes, as well as the difficulties associated with antibacterial
development in general [13, 22-24]. In the last decade, fragment-based approaches have become
an effective approach for inhibitor discovery against challenging targets, yet key questions remain
as for its utility in developing cross-class carbapenemase inhibitors, in both lead identification and
optimization [25-27]. Firstly, although fragments usually have low specificity, there has been no
report of fragment compounds displaying activity against both serine carbapenemases and MBLs,
with the majority of drug discovery efforts focusing on only one of the two groups of enzymes.
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Secondly, FBDD has mainly been applied to a single target, or multiple targets with high structural
similarity. It is unknown whether such an approach can be successfully implemented against two
groups of enzymes with as much structural and mechanistic differences as serine carbapenemases
and MBLs. This is particularly true for the lead-optimization process, when inhibitors also display
increased specificity [27].
In this study, I demonstrate that a fragment-based and structure-guided approach can be
successfully implemented in developing cross-class inhibitors against serine carbapenemases and
MBLs. The newly identified inhibitors provide novel scaffolds for antibiotic development
targeting carbapenem resistance, as well as valuable insights into how the unique broad-spectrum
activity of carbapenemases can be exploited in FBDD against multiple targets.

5.3 Results and Discussion

5.3.1 Structure-based inhibitor discovery against the serine carbapenemase KPC-2
My investigation into a broad-spectrum serine carbapenemase and MBL inhibitor began
with molecular docking to KPC-2. This was due to the relatively abundant knowledge of serine lactamases and the need for novel inhibitor chemotypes against KPC-2 in spite of the latest drug
discovery efforts (e.g., avibactam, relebactam, vaborbactam) [27, 28]. Docking to the ZINC
database of commercially available compounds led to the identification of a phosphonate based
compound 1 (Table 5.1).
Using a biochemical assay with nitrocefin as a substrate, we observed compound 1 to be a
moderate inhibitor of KPC-2 (Ki = 32.9 M). To improve compound activity, and to probe the
contributions of various functional groups to binding, five analogs were purchased and tested
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against KPC-2. All the purchased compounds displayed micromolar potency against KPC-2,
ranging from a Ki of 1.4 M to 154.4 M (Table 5.1). Compounds 2 and 3 had similar Ki’s of 13.4
M and 15.3 M, respectively. Compounds 4 and 5 are regioisomers with one methyl group
attached to either the C6 atom (compound 5) or the C7 atom (compound 4). Compound 5 had a Ki
of 154.4 M against KPC-2, whereas compound 4 had a Ki of 39.5 M. This suggests that KPC2 prefers the methyl substituent on the C7 atom as opposed to the C6 atom. This trend becomes
more apparent when comparing compounds 1 and 6, which are also regioisomers, having two
methyl groups, one attached to C6 and C7 (compound 1) or attached to C5 and C7 (compound 6).
Compound 6 had the best activity with a Ki of 1.4 M. As a result, SAR studies were focused on
derivatives of compound 6 in subsequent chemical synthesis efforts.
The synthesized compounds 7 through 10, like compound 6, had various substituents
attached to C5 and C7 to investigate how they would impact KPC-2 inhibition. At both C5 and C7
positions, increasing the size of the substitution (from –F, -CH3 to –Br) appears to improve the
inhibition, except for compound 7, with a methoxy group at C5. This replacement resulted in a
decrease in activity as compared to compound 6 (Ki = 5.7 M). The bromine substitution at C5,
compound 9, resulted in a potent inhibitor of KPC-2 (Ki = 0.47 M).
I was interested in seeing if changing the coumarin scaffold to a similar quinolone and
quinoline scaffold, would retain activity against KPC-2, due to the unfavorable pharmacokinetic
properties often associated with the coumarin ring. Three quinolone derivates (compounds 11, 12,
13) and two quinoline derivatives (compounds 14, 15) were synthesized and tested for inhibition.
Out of all the quinolone derivatives, compound 11 had the lowest level of inhibition (Ki = 122
M), possibly due to the lack of substituents on the C5 and C7 atoms. A similar result was seen
for compound 12 (Ki = 79.2 M), which also had no substituents on the C5 and C7 atoms, but
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possessed a methyl group attached to the N1 atom. Compound 13 was the most potent quinolone
derivative (Ki = 4.2 M), demonstrating similar activity to compound 6, due to both having methyl
groups located on C5 and C7. The two quinoline derivatives (compounds 14, 15) had the lowest
level of activity against KPC-2, possessing Ki’s of 447.1 M and 414.5 M, respectively.
Together, these results suggest that the exact chemical composition of a coumarin ring itself is not
essential for compound activity and demonstrates the potential of these compounds for further
development.
To better understand the structural basis of inhibition of the phosphonate based compounds,
I determined complex crystal structures with compounds 1, 2, 3, 6, and 9 (e.g., 1, 6, 9 Fig. 5.2 and
2, 3 Fig. S5.1) at resolutions of 1.50 Å and better. In the binding site, the conformation of the
inhibitors was unambiguously identified in the initial Fo-Fc electron density difference map
contoured at 2  (Fig. 5.2). For all the KPC-2 complex structures, the phosphonate moiety
establishes HBs with Ser70, Ser130, Thr235, and Thr237. In addition, the phosphonate group
forms a water-mediated HB with the backbone carbonyl of Thr216, and the carbonyl oxygen of
the inhibitors form a water-mediated HB with Arg220 and His274. The coumarin ring system
forms a pi-pi stacking interaction with Trp105. When examining the biochemical activities of
compounds 1, 6, and 9, it becomes apparent why compounds 6 and 9 have much better activity
against KPC-2 than compound 1. Moving the C6 methyl group (1) to the C5 position (6 and 9)
allows the coumarin ring to swing towards Trp105, a position that would otherwise cause steric
clashes between the C6 methyl group in 1 and Asn132. Concomitantly, there is a conformational
change in Trp105, that allows it to flip upward and closer to the ring system, forming stronger
hydrophobic interactions. In addition, the C5 substitution in compounds 6 and 9 also contributes
to non-polar interactions with Trp105.
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5.3.2 Inhibition of the MBLs NDM-1 and VIM-2
Expanding my inhibitor discovery efforts to two clinically relevant MBLs, NDM-1 and
VIM-2, I tested a select list of the phosphonate based coumarin, quinolone, and quinoline
compounds that displayed activity against KPC-2. Compound 6 was the most potent of the
compounds against NDM-1 (Ki = 33.8 M) and VIM-2 (Ki = 0.82 M). As observed in KPC-2,
NDM-1 and VIM-2 also prefer substituents on C5 and C7 for effective inhibition. This is reflected
in compounds with C5 and C7 substituents (6, 8, 9, and 13) having greater potency than
compounds lacking C5 and C7 substituents (11, 12, 14, 15) (Table 5.1). Interestingly, a fluorine
atom located on either C5 (compound 10) or both C5 and C7 (compound 8) appears to negatively
influence NDM-1 inhibition. This is demonstrated by no inhibition observed with compound 8 and
decreased inhibition of compound 10, as compared with compound 9 that has a bromine atom on
C5 instead of a fluorine.
NDM-1 complex structures were determined with compounds 1, 2, 3, 7, 8, 9, 11, 12, 13,
and 14, and VIM-2 complex structures with compounds 8 and 14. All structures were solved at
resolutions of 1.75 Å and better (Fig. 5.3, Fig. S5.2). In the binding site, the conformation of the
inhibitors was unambiguously identified in the initial Fo-Fc electron density difference map
contoured at 2  (Fig. 5.3, Fig. S5.2). The phosphonate group of each inhibitor coordinates with
both zinc ions in NDM-1 and VIM-2, displacing a hydroxide ion that is essential to catalysis [29].
For NDM-1, the phosphonate based coumarin, quinolone, and quinoline compounds form common
interactions within the active site. These interactions include the phosphonate moiety forming HBs
with Asn220 and with Asp124, which also forms a similar interaction with the hydroxide ion in
the apoenzyme; and the ring systems of the compounds forming pi-sigma interactions with Met67,
as well as non-polar interactions with Trp93 and Val73. Another commonly observed interaction
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is a pi-pi T-shaped interaction with Phe70 that every compound forms with NDM-1 except
compound 13.
Aside from the shared binding features, one key structural variation among the binding
poses of these compounds is the two different orientations of the ring system: one pointing the ring
carbonyl group away from Val73 (pose 1, e.g., compound 1, Fig. 5.3A) and the other towards it
(pose 2, e.g., compound 13, Fig. 5.3B). Pose 1 is favored by compounds with substitution at the
C6 position (e.g., 2, 3, Fig. S5.2) or at the O/N1 position (e.g., 11, 12, Fig. S5.2), in order to
enhance interactions with Val73 (e.g., using the C6 methyl group of 1) or avoid unfavorable
interactions with Phe70, respectively. The unfavorable interactions with Phe70 include both
potential steric clashes in the case of the N1 methyl group in 12, and the inability to HB with water,
in the case of the N1 hydrogen in 11. Pose 2 is favored by compounds with C5 substitutions for
additional interactions with His122 (e.g., -F in 8, Fig. 5.3C; -Br in 9, Fig. 5.3G). In the case of 13,
which has both C5 and N1 substitutions, pose 2 binding is observed in the active site, to increase
interactions with His122, while Phe70 moves slightly away from the compound to avoid
unfavorable interactions with the hydrogen at the N1 position.
Similar to NDM-1, compound 8 in VIM-2 adopts pose 2, and its phosphonate group forms
a HB with Asn210 and Asp118 (Fig. 5.3D). The ring system of compound 8 forms a pi-pi stacking
interaction with Tyr67 and Trp87, and a pi-pi T-shaped interaction with His240, like the contacts
between related compounds and Phe70/Trp93/His250 in NDM-1. Unique to VIM-2 is the presence
of Arg205 near the active site, which can establish a HB with the carbonyl oxygen of compound
8, which may result in tighter binding, particularly in comparison to NDM-1. Arg205 is also one
of the reasons why two copies of compound 14 were observed in the active of VIM-2 (Fig. 5.3F).
This is unlike any other inhibitors, where only one copy binds to the active site of KPC-2 or NDM119

1. The first copy of compound 14 has the phosphonate group forming HBs with the Arg205 side
chain and Asn210 backbone. The ring system forms a pi-pi T-shaped interaction with Tyr67 in
addition to a pi-pi stacking interaction with the second copy of compound 14. The second copy
binds in a way similar to 8, but is pushed away from Tyr67 by the first copy. The binding affinity
of compound 8 (Ki = 3.3 M) is roughly 6-fold lower than compound 14 (Ki = 22.3 M). This
may partially be explained by the more extensive interactions between compound 8 and the
protein. It is possible that both copies of 14 are relevant to enzyme inhibition as there appears to
be favorable interactions between the compounds as well, which can potentially enhance binding
to the protein.

5.3.3 Correlation of KPC-2, NDM-1, and VIM-2 inhibition
When comparing the activities of the synthesized phosphonate based inhibitors against
KPC-2 and VIM-2, a trend becomes apparent. These synthesized compounds represent the core
phosphonate ring scaffold with and without decorations at both C5 and C7 positions. As inhibitors
become more potent against KPC-2, they also demonstrate increasing potency against NDM-1 and
VIM-2 (Fig. 5.4). The correlation reflects the similar binding features of both proteins and the
relatively simple configuration of the compound, which reduces the likelihood of steric clashes.
Nevertheless, it is a striking trend considering the design and synthesis of these compounds were
originally intended for the SAR studies for KPC-2, based on the understanding of the commercially
available analogs.
The crystal structures of KPC-2 illustrate how the activity of the compounds are enhanced
as additional functional groups are added to the core scaffold. Compared with the smallest
compounds 14 and 15, the additional carbonyl group on 11 and 12 establishes new water-mediated
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interactions with Arg220 and His274; the subsequent substitutions at C5 and C7 positions in 8,
and particularly in 9, led to increased contacts with Leu167, Trp105, and neighboring residues.
Similar observations were made in NDM-1 and VIM-2 complex structures. For NDM-1, the larger
-Br of 9 makes new contacts with His122, while for VIM-2, the carbonyl group of 8 augments
inhibitor binding through a HB with Arg205.

5.3.4 Susceptibility of clinical isolates to compounds 9, 11, and 13
To investigate the effects of these inhibitors on bacterial cells, compounds 9, 11, and 13
were selected and tested (at 128 g/mL), in combination with the carbapenem antibiotic imipenem,
against Gram-negative clinical isolates known to produce carbapenemases (Table 5.2). Compound
9 restored susceptibility to imipenem in a K. pneumoniae strain producing KPC-2, and reduced the
MIC by 64-fold. It also decreased the MIC for imipenem by 4-fold in an NDM-1 producing E. coli
strain, and 2-fold in an NDM-1 producing K. pneumoniae strain. Compound 9 did not have any
activity against NDM-1 producing E. cloacae. Compared to KPC-2, the lower cell-based activity
of 9 against NDM-1 correlates with the different in vitro activities in biochemical testing. The
variation among different bacterial strains underscores the influence of other biological factors on
the cell-based activity of these inhibitors. This is further demonstrated by the lack of activity of 9
against a VIM-2 producing P. aeruginosa strain, even though our nitrocefin inhibition assays
demonstrated compound 9 to be a micromolar inhibitor of VIM-2 (Ki = 1.3 M). Compound 11
was less effective than compound 9 in reducing the MIC of imipenem against the KPC-2 producing
K. pneumoniae. It displayed similarly low activity, or no effect against NDM-1 producing E. coli,
K. pneumoniae, and E. cloacae. Compound 13 was comparable to compound 9 at reducing the
MIC of imipenem by 64-fold in KPC-2 producing K. pneumoniae, and 4-fold in NDM-1 producing
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E. coli, but was not able to reduce the MIC in NDM-1 producing K. pneumoniae/E. cloacae, and
VIM-2 producing P. aeruginosa. Overall these results suggest that the phosphonate inhibitors were
able to cross the cell envelope and inhibit the carbapenemases produced by pathogenic Gramnegative bacteria.

5.4 Conclusions
Serine carbapenemases and MBLs produced by Gram-negative pathogens are a serious
threat to human health due to their multi-drug resistant nature. The development of an inhibitor
that can target both serine carbapenemases and MBLs is imperative. My biochemical, X-ray
crystallographic, and cell-based studies have demonstrated, for the first time, that rational design
of a cross-class, non-covalent, broad-spectrum inhibitor against serine carbapenemases and MBLs
is an achievable task. More importantly, my results provide valuable chemical and structural
information, as well as important insights for future drug discovery efforts against these enzymes.
My inhibitor discovery efforts focused on fragment-based approaches, which are uniquely
suitable for identifying novel inhibitor chemotypes for difficult bacterial targets. Nevertheless, as
evidenced by the lack of published results in this area, identifying suitable cross-class fragment
inhibitors for carbapenemases is challenging, particularly for chemical scaffolds that enable lead
optimization for both groups of enzymes. The phosphonate compounds provide a promising novel
fragment chemotype for this purpose, and represent the first non-covalent inhibitors with
comparable binding affinities against both serine -lactamases and MBLs. In both KPC-2 and
NDM-1/VIM-2, the inhibitors reside in an area usually occupied by the -lactam core of the
substrates, and is thus essential for enzyme activity (Fig. 5.5). In KPC-2, the phosphonate moiety
is placed in a subpocket formed by Ser130, Thr235, and Thr237, which also happens to interact
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with the C3’/4’ carboxylate group of the -lactam substrate [30]. In NDM-1/VIM-2, the
phosphonate group interacts with both zinc ions and neighboring residues important for binding to
the same substrate C3’/4’ carboxylate group, as well as the -lactam carbonyl group, which is
converted to a carboxylate group after the hydrolysis reaction catalyzed by the -lactamases [4,
13]. The cell-based activity of these inhibitors further supports these compounds’ potential as lead
scaffolds for antibiotic development. In addition, the observation of an acetate molecule in the
NDM-1 active site informs future fragment-based lead-optimization efforts, by highlighting an
underutilized binding hot spot that also contributes to the binding of the C3’/4’ carboxylate group
in previous NDM-1 complexes [31, 32].
Most significantly, my results have underscored the versatility of carbapenemases in ligand
binding, and demonstrated that this feature can be a double-edged sword for carbapenemases,
presenting a unique opportunity for drug discovery. The relative open and hydrophobic features of
carbapenemase active sites, particularly in the metalloenzymes, have led to the hypothesis that
these binding surfaces may lead to increased druggability [30]. Our crystal structures have
illustrated the important contributions of a number of hydrophobic residues to ligand binding, such
as Trp105/Leu167 in KPC-2, Val73/Trp93/Met67/Phe70 in NDM-1, and Trp87/Tyr67 in VIM-2.
In addition, the conformational variation of the protein residues and ligand binding poses observed
in our structures suggest that residue flexibility and the relative openness of the active site affords
the carbapenemases important adaptability in binding to small molecules. Examples of protein
structural flexibility include: Trp105 in KPC-2, as shown by its varied conformations in binding
to compounds 1 and 6, and particularly in comparison to the more rigid Tyr105 in other class A
serine -lactamases [33-36]; Phe70 and the surrounding loop in NDM-1, as indicated by their
movement in binding to compound 13; and Arg205 in VIM-2, adopting different conformations
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binding to compounds 8 and 14, and making important HBs in both cases. The relative
openness/flat features of MBLs is partially demonstrated by how two drastically different ligand
conformations, caused by flipping of the ring system (e.g., 1 vs 13, Fig. 5.3A, B), can both be
accommodated in NDM-1 active site, allowing the ligand to maximize its contacts with the protein
while having minimal steric clashes.
These unique structural features endow carbapenemases with a certain level of ligand
binding promiscuity. The openness of the active site reduces the chances of steric clashes with
small molecules, whereas increased hydrophobicity compensates the diminished shape
complementarity. Albeit to a lesser extent, these properties are reminiscent of other proteins
capable of binding to a wide range of ligands, such as efflux pumps [37, 38]. For carbapenemases,
such qualities may explain their ability to bind and hydrolyze nearly all -lactam antibiotics, but
may also expose a weakness to novel inhibitor binding. For drug discovery against these enzymes,
this is particularly valuable for the lead optimization process. The correlation between the inhibitor
activity, particularly with VIM-2 and KPC-2, is very informative, considering that the compounds
were designed and synthesized to target KPC-2. The hydrophobicity, flexibility, and relative
flatness of the VIM-2 active site enables it to accommodate and adapt to the ligand to maximize
the interactions, as the size and complexity of the ligand increases. This correlation is also
especially striking when compared to previous studies on CTX-M class A and AmpC class C lactamases. Both are serine-based enzymes and have more active site similarities than those shared
by KPC-2 and VIM-2 [39]. In the previous fragment-based inhibitor discovery efforts, the starting
fragment inhibitors have low specificity with mM range affinities against both enzymes. But as
the compound size rises and the binding affinity against CTX-M-9 improves to mid-low M, the
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specificity significantly increases with the binding affinity, remaining at mM or undetectable for
AmpC.
There have been previous efforts to develop cross-class inhibitors of serine -lactamases
and MBLs, including the most recent success of a series of cyclic boronate compounds [22, 40,
41]. However, these inhibitors usually use two different mechanisms to inhibit serine -lactamases
and MBLs separately, and provide relatively little information on rational design of novel cross
class inhibitors, particularly concerning the challenges in the lead optimization process. In the case
of cyclic boronates, they rely on the reactivity of boron groups to form covalent bonds with the
catalytic serine of serine -lactamases, and consequently achieve high binding affinity. In
comparison, the boronates behave as non-covalent inhibitors for MBLs. As a result, the lead
optimization process would only need to focus on increasing the binding affinity against the
metalloenzymes, with some consideration of avoiding steric clashes in serine -lactamase active
sites.
In conclusion, my studies have uncovered novel cross-class inhibitors against two groups
of clinically important carbapenemases. Together with the new insights into ligand binding by
these enzymes and FBDD, these compounds provide a promising strategy to develop novel
antibiotics against -lactam resistance in bacteria.

5.5 Materials and Methods

5.5.1 KPC-2 expression and purification.
KPC-2 was expressed and purified as previously described [30].
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5.5.2 NDM-1 expression and purification
The gene encoding NDM-1 (residues 29-270) was cloned into the pET-SUMO vector with
an N-terminal SUMO-tag. The plasmid containing SUMO-NDM-1 was transformed into E. coli
BL21 (DE3) cells. For SUMO-tag NDM-1, bacteria were grown overnight at 30 oC with shaking
in 50 mL LB broth supplemented with 100 g/mL ampicillin. Two liters of LB broth supplemented
with 100 g/mL ampicillin were each inoculated with 10 mL of overnight bacterial culture.
Cultures were then grown at 37 oC until an OD600 of 0.6-0.7. Protein expression was then initiated
by the addition of IPTG (final concentration 0.5 mM), followed by growth for 16 h at 20 oC. Cells
were pelleted by centrifugation and stored at -80 oC until further use.
The SUMO-tag NDM-1 -lactamase was purified by nickel affinity chromatography and
gel filtration. Briefly, the cell pellets were thawed and re-suspended in 40 mL of buffer A (20 mM
HEPES pH 7.4, 0.5 M NaCl, 20 mM imidazole) with one complete protease inhibitor cocktail
tablet (Roche) and disrupted by sonication, followed by ultracentrifugation to clarify the lysate.
After ultracentrifugation, the supernatant was passed through a 0.22 m filter before loading onto
a 5 mL HisTrap HP affinity column (GE Healthcare Life Sciences, USA) pre-equilibrated with
buffer A. SUMO-tag NDM-1 was eluted by a linear imidazole gradient (20 mM to 500 mM).
Fractions were analyzed by SDS-PAGE. Fractions containing SUMO-tag NDM-1 were buffer
exchanged into 20 mM HEPES pH 7.0, 100 mM NaCl. Cleavage of the SUMO-tag was then
carried out with ULP-1 protease overnight at room temperature and then concentrated using a 10k
NMWL Amicon Ultra-15 Centrifugal Filter Unit. The sample was then loaded back onto a nickel
affinity column and the flow through was collected, containing the untagged NDM-1. NDM-1 was
concentrated and loaded onto a gel filtration column (GE Healthcare Life Sciences) preequilibrated with 50 mM HEPES, 150 mM NaCl, and 50 M ZnSO4. Protein concentration was
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determined by absorbance at 280 nm using an extinction coefficient of 27,960. SDS-PAGE
analysis indicated that the eluted protein was more than 95% pure.

5.5.3 VIM-2 expression and purification.
The gene encoding VIM-2 (residues 27-266) was custom synthesized and inserted into a
vector with an N-terminal His-tag. The plasmid containing His-tag VIM-2 was transformed into
Rosetta2 (DE3) E. coli cells. For His-tag VIM-2, bacteria were grown overnight at 30 oC with
shaking in 50 mL LB broth supplemented with 50 g/mL kanamycin. Two liters of terrific broth
supplemented with 50 g/mL kanamycin were each inoculated with 10 mL of overnight bacterial
culture. Cultures were then grown at 37 oC until an OD600 of 0.6-0.7. Protein expression was then
initiated by the addition of IPTG (final concentration 0.5 mM), followed by growth for 16 h at 20
o

C. Cells were pelleted by centrifugation and stored at -80 oC until further use.
VIM-2 was purified by nickel affinity chromatography, anion exchange, and gel filtration

chromatography. Briefly, the cell pellets were thawed and re-suspended in 40 mL of buffer A (50
mM HEPES pH 7.5, 150 mM NaCl, 20 mM imidazole, 50 M ZnSO4) with one complete protease
inhibitor cocktail tablet (Roche) and disrupted by sonication, followed by ultracentrifugation to
clarify the lysate. After ultracentrifugation, the supernatant was passed through a 0.22 m filter
before loading onto a 5 mL HisTrap HP affinity column (GE Healthcare Life Sciences, USA) preequilibrated with buffer A. VIM-2 was eluted by a linear imidazole gradient (20 mM to 500 mM).
Fractions were analyzed by SDS-PAGE. Fractions containing VIM-2 were buffer exchanged into
50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM DTT. Cleavage of the His-tag was then carried out
with TEV protease overnight at room temperature and then concentrated using a 10k NMWL
Amicon Ultra-15 Centrifugal Filter Unit. The sample was then loaded back onto a nickel affinity
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column and the flow through was collected, containing the untagged VIM-2. VIM-2 was then
subjected to anion exchange chromatography, using a linear gradient from buffer A (20 mM TrisHCl pH 7.5) to buffer B (20 mM Tris-HCl pH 7.5, 1 M NaCl). VIM-2 was concentrated and loaded
onto a gel filtration column (GE Healthcare Life Sciences) pre-equilibrated with 50 mM HEPES
pH 7.0, 150 mM NaCl, 50 M ZnSO4. Protein concentration was determined by absorbance at 280
nm using an extinction coefficient of 25,669. SDS-PAGE analysis indicated that the eluted protein
was more than 95% pure.

5.5.4 Molecular docking
The program DOCK 3.5.4 [42] was used to screen the fragment subset of the ZINC
database of small molecules [43], using an in-house apo KPC-2 structure as a receptor template.
The conserved catalytic water was left in the active site, while all other waters were removed.
Docking was performed as previously described [39].

5.5.5 Steady-state kinetic analysis
Steady-state kinetic parameters were determined by using a Biotek Cytation Multi-Mode
Reader. For KPC-2, each assay was performed in 100 mM Tris-HCl pH 7.0, 0.01% Triton X-100
at 37 oC. Vmax and Km were determined from initial steady-state velocities from nitrocefin read at
a wavelength of 486 nm. The kinetic parameters were obtained using the non-linear portion of the
data to the Henri-Michaelis (equation 1) using SigmaPlot 12.5.
V= Vmax [S]/(Km + [S])

(1)
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IC50, defined as the inhibitor concentration that results in a 50% reduction of nitrocefin (20 m)
hydrolysis was determined by measurements of initial velocities after mixing 1 nM of KPC-2 with
increasing concentrations of inhibitors. The inhibition constant (Ki) was calculated according to
equation 2:

Ki= IC50/([S]/Km + 1)

(2)

For NDM-1 and VIM-2, the procedures were the same as above except the assay was performed
in 50 mM HEPES pH 7.2, 50 M ZnSO4, 0.01% Triton X-100, 1 g/mL bovine serum albumin
(BSA).

5.5.6 Crystallization and soaking experiments
KPC-2 was crystallized as described previously [30]. KPC-2 crystals were soaked in 1.44
M sodium citrate containing 10 mM inhibitor for approximately 2 h. KPC-2 crystals were then
cryoprotected in a solution containing 1.15 M sodium citrate, 20% (v/v) glycerol and flash-frozen
in liquid nitrogen. Crystals of NDM-1 were grown at 20 °C using hanging-drop vapor diffusion.
Protein solutions (10-20 mg/mL) in 50 mM HEPES, 150 mM NaCl, and 50 M ZnSO4 were mixed
1:1 (v/v) with reservoir solution containing 50 mM potassium phosphate dibasic, 10 mM CaCl2
and 25% (w/v) PEG8000. Crystals typically formed in two days. To obtain the ligand bound
structures, NDM-1 crystals were soaked in a solution of 50 mM sodium acetate pH 3.85, 25%
(w/v) PEG8000 and 10 mM inhibitor for 1 h. The soaked crystals were cryo-protected in a solution
containing 50 mM sodium acetate pH 3.85, 25% (w/v) PEG8000, and 20% (v/v) glycerol and
flash-frozen in liquid nitrogen. Crystals of VIM-2 were grown at 20 °C using hanging-drop vapor
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diffusion. Protein solutions (10-20 mg/mL) in 50 mM HEPES, 150 mM NaCl, and 50 M ZnSO4
were mixed 1:1 (v/v) with reservoir solution containing 200 mM calcium acetate, 20% (w/v)
PEG3350, and 1 mM TCEP. Crystals typically formed in two days. To obtain the ligand bound
structures, VIM-2 crystals were soaked in a solution of 50 mM sodium acetate pH 3.85, 25% (w/v)
PEG8000 and 10 mM inhibitor for 1 h. The soaked crystals were cryo-protected in a solution
containing 50 mM sodium acetate pH 3.85, 25% (w/v) PEG8000, and 20% (v/v) glycerol and
flash-frozen in liquid nitrogen.

5.5.7 Data collection and structure determinations
Data for the KPC-2, NDM-1, and VIM-2 complex structures were collected using
beamlines 22-ID-D and 23-ID-D at the Advanced Photon Source (APS), Argonne, Illinois and
beamline 8.3.1 at the Advanced Light Source (ALS), Berkeley, California. Diffraction data were
indexed and integrated with iMosflm [44] and scaled with SCALA [45] from the CCP4 suite [46].
Phasing was performed using molecular replacement with the program Phaser [47] of the Phenix
suite [48], with the KPC-2 structure (PDB ID code: 5UL8), NDM-1 (PDB ID code: 4TYF), and
VIM-2 (PDB ID code: 4BZ3). Structure refinement was performed using phenix.refine [49] of the
Phenix suite and model building in WinCoot [50]. The unbiased Fo-Fc electron density maps were
generated prior to refinement with compound. The program eLBOW [51] in Phenix was used to
obtain geometry restraint information. The final model qualities were assessed using MolProbity
[52]. Figures were generated in PyMOL 1.3 (Schrödinger) in which structural alignments were
generated using pairwise scores [53].
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5.6 Note to Reader #1
Supplementary figures (Fig. S5.1 and S5.2) are located in Appendix 3.
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Avibactam

Vaborbactam

Aspergillomarasmine A

Figure 5.1. Clinical and pre-clinical serine carbapenemase and MBL inhibitors.
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Figure 5.2. X-ray crystal structures of KPC-2 bound to phosphonate inhibitors. (A) compound 1, (B) compound 6, and (C)
compound 9. KPC-2 residues are colored gray, compounds are colored in green, and the unbiased F o-Fc map is colored in gray and
contoured at 2 .
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Figure 5.3. X-ray crystal structures of NDM-1 and VIM-2 bound to phosphonate inhibitors. (A) NDM-1 with 1. (B) NDM-1 with
13. (C) NDM-1 with 8. (D) VIM-2 with 8. (E) NDM-1 with 14. (F) VIM-2 with 14. (G) NDM-1 with 9. Fo-Fc map is colored in gray
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(A)

(B)

Figure 5.4. Correlation of -lactamase inhibition. (A) KPC-2 vs. NDM-1 inhibition and (B) KPC-2 vs.
VIM-2 inhibition with select phosphonate compounds.
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Figure 5.5. Superimposition of phosphonate inhibitor and -lactam product complexes.
Superimposition of (A) KPC-2/compound 9 and KPC-2/cefotaxime product. KPC-2/compound 9
complex are colored in gray and green, respectively. KPC-2/cefotaxime product are both colored in
blue. Superimposition of (B) NDM-1/compound 9 and NDM-1/ampicillin product. NDM-1/compound
9 complex are colored in gray and green, respectively. NDM-1/ampicillin product are both colored in
blue.
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Table 5.1. Nitrocefin inhibition assay of phosphonate compounds tested against KPC-2, NDM-1, and VIM-2

MW

Ki (KPC-2) M

Ki (NDM-1) M

Ki (VIM-2) M

1

268.2

32.9

44.3

2.1

2

270.2

13.4

123.7

2.1

3

284.2

15.3

N/A

N/A

4

254.2

39.5

N/A

N/A

5

254.2

154.4

N/A

N/A

6

268.2

1.4

33.8

0.82

7

284.2

5.7

N/A

N/A

8

276.1

8.9

No inhibition

3.3

9

333.1

0.47

65.4

1.3

10

272.2

3.3

230.2

3.3

11

239.2

122

190.2

6.4

12

253.2

79.2

81.0

7.5

13

267.2

4.2

56.2

3.4

14

223.2

447.1

741.3

22.3

15

223.2

414.5

No inhibition

30.3

Compound #

Structure
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Imipenem/
Compound 11

Imipenem/
Compound 13

Phenotype
NDM-1
KPC-2
NDM-1
NDM-1
VIM-2

Imipenem/
Compound 9

Test Organism
E. coli
K. pneumoniae
K. pneumoniae
E. cloacae
P. aeruginosa

Imipenem

Table 5.2. In vitro activity of phosphonate compounds when combined with imipenem. Compounds 9, 11, and 13 were
tested at 128 g/mL fixed concentration with imipenem against KPC-2, NDM-1, and VIM-2 producing bacteria

8
64
>64
2
>64

2/128
1/128
32/ 128
2/128
>64/ 128

2/ 128
4/ 128
32/ 128
2/ 128
>64/128

2/128
1/128
64/ 128
2/128
>64/ 128
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Chapter 6:
Summary

Production of -lactamase enzymes by Gram-negative pathogens is a major cause of
bacterial resistance against the commonly used -lactam antibiotics. -Lactam resistance mediated
by -lactamases can be overcome through the use of BLIs. Clavulanic acid, sulbactam, and
tazobactam are examples of clinically used BLIs that demonstrate activity against class A and D
-lactamases. Unfortunately, because these inhibitors possess a -lactam ring, they are susceptible
to degradation by -lactamases such as KPC-2 (class A serine enzyme) and NDM-1/VIM-2 (class
B metalloenzymes). As a result, a better understanding of the catalytic mechanism of -lactamases
is crucial in discovering novel inhibitors active against both serine and metalloenzymes.
The first project addressed the cephalosporinase and carbapenemase activity of the serine
carbapenemase KPC-2. Three crystal structures: apo, hydrolyzed cefotaxime, and hydrolyzed
faropenem, provided experimental insights into the substrate recognition of KPC-2 and how
alternative conformations of Ser70 and Lys73 promote expulsion of the hydrolyzed product from
the active site. The ability of KPC-2 to bind such a wide variety of -lactam substrates can be
exploited through rational drug design to engineer high affinity inhibitors.
The second project focused on understanding the proton transfer process involved in the
mechanism of avibactam inhibition against serine -lactamases. Ultrahigh resolution X-ray
crystallography of CTX-M-14 bound with avibactam allowed for elucidation of protonation states
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of the key catalytic residues, Lys73, Ser130, and Glu166. Avibactam impedes a critical proton
transfer between Glu166 and Lys73, keeping these residues as neutral species, and thereby leaving
a stable EI complex resistant to hydrolysis.
The third project investigated the influence of binding kinetics on vaborbactam inhibition
of KPC-2. The binding kinetic experiments revealed that vaborbactam has an extremely slow offrate with KPC-2 leading to a residence time of close to 1,000 min, which is much greater than the
bacterial generation time (~ 20 min). The long residence time of vaborbactam translated to
favorable in vitro and in vivo efficacy. A high-resolution crystal structure of vaborbactam bound
to KPC-2 demonstrated the covalent bond with the catalytic serine as well as the extensive noncovalent interactions that contribute to binding affinity.
The final project focused on discovering inhibitors that could simultaneously target serine
-lactamases and MBLs. Using molecular docking and FBDD, a series of phosphonate-based
compounds were identified that displayed micromolar potency against KPC-2, NDM-1, and VIM2. Crystal structures of these inhibitors with KPC-2, NDM-1, and VIM-2 demonstrated their
interactions with conserved active site features. The phosphonate-based inhibitors reduced the
MIC of imipenem against a K. pneumoniae strain expressing KPC-2 and an E. coli strain
expressing NDM-1. Ultimately, these phosphonate-based compounds will serve as scaffolds for
the development of potent inhibitors targeting serine -lactamases and MBLs.
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Figure S4.1. Lineweaver-Burk plot of KPC-2 inhibition by vaborbactam.
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Figure S4.2. KPC-2 inactivation profile using boronic acid BLIs.
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Figure S4.3. Time-dependence of vaborbactam inhibition of KPC-2.
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Figure S4.4. Vaborbactam and tazobactam kinetic behavior with KPC-2.
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Figure S4.5. Jump dilution can reverse vaborbactam inhibition of KPC-2.
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Table S4.1. MIC of various -lactams against P. aeruginosa expressing KPC-2 and KPC-2 S130G

Plasmid

Ceftazidime

Cefepime

Carbenicillin

Piperacillin

Meropenem

Aztreonam

vector

2

0.125

0.5

0.25

0.125

1

KPC-2

32

128

>512

128

128

16

KPC-2 S130G

1

0.125

128

64

0.25

0.25
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Table S4.2. X-ray data collection and refinement statistics

Structure

KPC-2 with vaborbactam

Data Collection
Space group

P22121

Cell dimensions
a, b, c (Å)

55.77, 59.97, 77.72

(°)

90, 90, 90

Resolution (Å)
No. of unique reflections
Rmerge (%)
I/σ(I)

47.48 -1.25 (1.295-1.25)
72,556 (7159)
9.0 (91.2)
8.9 (1.8)

Completeness (%)
Multiplicity

99.7 (99.7)
5.8 (5.8)

Refinement
Resolution (Å)

47.48 -1.25

Rwork (%)

14.7 (26.9)

Rfree (%)

17.0 (28.6)

No. atoms
Protein
Ligand/Ion
Water
B-factors (Å2)
protein
ligand/ion
water
RMS deviations
Bond lengths (Å)

2160
66
305
14.98
28.65
35.29
0.007

Bond angles (°)
Ramachandran plot

1.07

favored (%)

98.88

allowed (%)
outliers (%)
PDB code

1.12
0
5WLA
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Figure S5.1. KPC-2 bound to (A) compound 2 and (B) compound 3. Compounds are colored in green and the
unbiased Fo-Fc map is colored in gray and contoured at 2 .
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Figure S5.2. NDM-1 bound to (A) compound 2, (B) compound 3, (C) compound 7, (D) compound 11, and (E)
compound 12. Compounds are colored in green and the unbiased Fo-Fc map is colored in gray and contoured at 2 .
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Figure S5.2. Continued.
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